

## Publikationen

### Rheumazentrum Ruhrgebiet seit 2000

1. Kiltz U, Andreica I, Igelmann M, Kalthoff L, Krause D, Schmitz E, McKenna SP, Braun J. Standardized documentation of health-related quality of life in patients with psoriatic arthritis Validation of the German version of the psoriatic arthritis quality of life (PsAQoL) questionnaire. *Z Rheumatol* 2021;80:122-31.
2. Thomasius F, Buehring B. Risk assessment in osteoporosis Time-tested and new approaches. *Internist* 2021;62:463-73.
3. Sivera F, Alunno A, Najm A, Avcin T, Baraliakos X, Bijlsma JW, Badreh S, Burmester G, Cikes N, Da Silva JAP, Damjanov N, Dougados M, Dudler J, Edwards CJ, Iagnocco A, Liote F, Nikiphorou E, van Onna M, Stones SR, Vassilopoulos D, Haines C, Ramiro S. 2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. *Ann Rheum Dis* 2021;80:65-70.
4. Ortolan A, Kiltz U, Doria A, Aggarwal A, Ramonda R. Do we believe in non-radiographic axial spondyloarthritis? A debate. *Autoimmun Rev* 2021;20:3.
5. Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. *Ann Rheum Dis* 2021;80:71-87.
6. Mader R, Pappone N, Baraliakos X, Eshed I, Sarzi-Puttini P, Atzeni F, Bieber A, Novofastovski I, Kiefer D, Verlaan JJ, Ambrosino P, Buskila D, Armas JB, Khan MA. Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component. *Curr Rheumatol Rep* 2021;23:6.
7. Lorenz HM, Aringer M, Braun J, Hoyer BF, Krause A, Meyer-Olson D, Mucke J, Rudwaleit M, Schneider M, Sewerin P, Spathling-Mestekemper S, Specker C, Voormann A, Wagner U, Wendler J, Schulze-Koops H. Mission statement from rheumatologists in the German Society of Rheumatology (DGRh e. V.) We live rheumatology. *Z Rheumatol* 2021;80:10-2.
8. Lopez-Medina C, Molto A, Sieper J, Duruoz T, Kiltz U, Elzorkany B, Hajjaj-Hassouni N, Burgos-Vargas R, Maldonado-Cocco J, Ziade N, Gavali M, Navarro-Compan V, Luo SF, Monti S, Tae-Jong K, Kishimoto M, Pimentel-Santos FM, Gu JR, Schiotis R, van Gaalen FA, Geher P, Magrey M, Vodnizza SEI, Bautista-Molano W, Maksymowych W, Machado PM, Landew R, van der Heijde D, Dougados M. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. *RMD Open* 2021;7:12.
9. Lakomek HJ, Krause A, Braun J, Hellmich B, Klass M, Lorenz H, Schneider M, Schulze-Koops H, Specker C. Future of acute inpatient rheumatology in Germany. Statement of the Boards of the German Society for Rheumatology and the Association of Rheumatological Acute Clinics on hospital planning North-Rhine/Westphalia 2019 for the discipline rheumatology. *Z Rheumatol* 2021;80:103-6.
10. Krause D, Krause C, Rudolf H, Baraliakos X, Braun J, Schmitz E. Dose tapering of biologic agents in patients with rheumatoid arthritis-results from a cohort study in Germany. *Clin Rheumatol* 2021;40:887-93.

11. Kiltz U, Celik A, Tsiami S, Buehring B, Baraliakos X, Andreica I, Kiefer D, Braun J. Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study. *RMD Open* 2021;7:9.
12. Kiltz U, Buschhorn-Milberger V, Vaupel K, Braun J. Gout: Current Epidemiology, Comorbidities, Complications and Socioeconomic Consequences. *Aktuelle Rheumatol* 2021;46:36-41.
13. Kiltz U, Andreica I, Igelmann M, Kalthoff L, Krause D, Schmitz E, McKenna SP, Braun J. Erratum to: Standardized documentation of health-related quality of life in patients with psoriatic arthritis. Validation of the German version of the psoriatic arthritis quality of life (PsAQoL) questionnaire (vol 49, pg 531, 2020). *Z Rheumatol* 2021;80:131-.
14. Hong N, Siglinsky E, Krueger D, White R, Kim CO, Kim HC, Yeom Y, Binkley N, Rhee Y, Buehring B. Defining an international cut-off of two-legged countermovement jump power for sarcopenia and dysmobility syndrome. *Osteoporosis Int* 2021;32:483-93.
15. Han Q, Zheng ZH, Zhang K, Ding J, Baraliakos X, Zhu P. A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features. *Front Immunol* 2021;12:7.
16. Elewaut D, Braun J, Anderson JK, Arikian D, Chen S, Hojnik M, De Craemer AS, Curtis JR. Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases. *Arthritis Care Res* 2021;73:289-95.
17. Deodhar A, Blanco R, Dokoupilova E, Hall S, Kameda H, Kivitz AJ, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Richards HB, Haemmerle S, Braun J. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. *Arthritis Rheumatol* 2021;73:110-20.
18. Buehring B, Gluer CC, Jakob F, Karberg K, Kornak U, Thomasius F. Obituary for Dieter Felsenberg. *Osteoporosis Int* 2021;32:1247-8.
19. Braun J, Krause D, Kiltz U. The efficacy of a nurse-led interventional program to improve the health of patients with axial spondyloarthritis. *Rheumatology* 2021;60:487-8.
20. Baraliakos X, Witte T, De Clerck L, Frediani B, Collantes-Estevez E, Katsifis G, VanLunen B, Kleine E, Hoepken B, Bauer L, Goodson N. Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe. *Rheumatology* 2021;60:113-24.
21. Baraliakos X, Van den Bosch F, Machado PM, Gensler LS, Marzo-Ortega H, Sherif B, Quebe-Fehling E, Porter B, Gaillez C, Deodhar A. Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. *Rheumatol Ther* 2021;8:273-88.
22. Baraliakos X, Richter A, Feldmann D, Ott A, Buelow R, Schmidt CO, Braun J. Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population? *Ann Rheum Dis* 2021;80:469-74.
23. Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D'Angelo S, Schulz B, Rissler M, Nagar K, Perella C, Coates LC. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. *Ann Rheum Dis* 2021;80:582-90.
24. Baraliakos X, Ghadir A, Fruth M, Kiltz U, Redeker I, Braun J. Which Magnetic Resonance Imaging Lesions in the Sacroiliac Joints Are Most Relevant for Diagnosing Axial Spondyloarthritis? A Prospective Study Comparing Rheumatologists' Evaluations With Radiologists' Findings. *Arthritis Rheumatol* 2021;73:800-5.

25. Baraliakos X, Ghadir A, Fruth M, Kiltz U, Reddeker I, Braun J. Which Magnetic Resonance Imaging Lesions in the Sacroiliac Joints Are Most Relevant for Diagnosing Axial Spondyloarthritis? A Prospective Study Comparing Rheumatologists' Evaluations With Radiologists' Findings. *Arthritis Rheumatol* 2021;73:816-25.
26. Andreica I, Guminski B, Sokolar J, Patru A, Baraliakos X, Braun J. Threat of a SARS-CoV-2 endemic in a large hospital specialized in rheumatic diseases-relative all clear through consistent testing. *Z Rheumatol* 2021;80:45-7.
27. Andreasen RA, Kristensen LE, Egstrup K, Baraliakos X, Strand V, Horn HC, Wied J, Schiottz-Christensen B, Aalykke C, Hansen IMJ, Ellingsen T, Christensen R. The Prognostic Value of Pain Phenotyping in Relation to Treatment Outcomes in Patients with Axial Spondyloarthritis Treated in Clinical Practice: A Prospective Cohort Study. *J Clin Med* 2021;10:13.
28. Zabotti A, Finzel S, Baraliakos X, Aouad K, Ziade N, Iagnocco A. Imaging in the preclinical phases of rheumatoid arthritis. *Clin Exp Rheumatol* 2020;38:536-42.
29. van der Heijde D, Gensler LS, Deodhar A, Baraliakos X, Poddubnyy D, Kivitz A, Farmer MK, Baeten D, Goldammer N, Coarse J, Oortgiesen M, Dougados M. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. *Ann Rheum Dis* 2020;79:595-604.
30. Vahldiek JL, Schaafs LA, Niehues BK, Hamm B, Niehues SM. Effect of Different Iodine Concentrations on Patient-Reported Discomfort in Contrast-Enhanced Computed Tomography: A Prospective Comparative Trial. *Rofort Fortschr Gebiet Rontgenstrahlen Bildgeb Verfahr* 2020;192:945-51.
31. Stal R, van Gaalen F, Sepriano A, Braun J, Reijnierse M, van den Berg R, van der Heijde D, Baraliakos X. Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression. *Rheumatology* 2020;59:3776-83.
32. Schneider M, Baseler G, Funken O, Heberger S, Kiltz U, Klose P, Kruger K, Langhorst J, Mau W, Oltman R, Richter B, Seitz S, Sewerin P, Tholen R, Weseloh C, Witthoft M, Specker C. Management of early rheumatoid arthritis Interdisciplinary guideline. *Z Rheumatol* 2020;79:S1-S38.
33. Salinas RG, Marin J, Aguilar G, Ruta S, Aguerre D, Baraliakos X. Recognition of spondyloarthritis lesions on magnetic resonance imaging: Results of an educational intervention. *Int J Rheum Dis* 2020;23:1651-5.
34. Sahr T, Kiltz U, Weseloh C, Kallinich T, Braun J. Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerance to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology. *Z Rheumatol* 2020;79:943-51.
35. Rodrigues-Manica S, Cruz E, Ramiro S, Sousa S, Aguiar R, Sepriano A, Machado P, Branco J, Kiltz U, Pimentel-Santos F. The European Portuguese version of the ASAS Health Index for Patients with Spondyloarthritis: measurement properties. *Acta Reumatol Port* 2020;45:26-33.
36. Reusch A, Braun J, Lakomek HJ, Lakomek M, Lind-Albrecht G, Janiche H, Cattelaens K, Hammel L, Demtroder F, Ehlebracht-Konig I, Polnau U, Specker C, Gerlich C, Kuffner R. Flexible programs and advanced training for rheumatological patient education. *Z Rheumatol* 2020;79:74-7.
37. Regierer AC, Weiss A, Baraliakos X, Zink A, Listing J, Strangfeld A. RABBIT-SpA: a new disease register for axial spondyloarthritis and psoriatic arthritis. *Z Rheumatol* 2020;79:135-42.
38. Poddubnyy D, Hammel L, Heyne M, Veit J, Jentzsch C, Baraliakos X. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment

in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate. *BMJ Open* 2020;10:7.

39. Palominos PE, Coates L, Kohem CL, Orbai AM, Smolen J, de Wit M, Kiltz U, Leung YY, Canete JD, Scivo R, Balanescu A, Dernis E, Meisalu S, Soubrier M, Aydin SZ, Gaydukova I, Kalyoncu U, Gossec L. Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. *Joint Bone Spine* 2020;87:449-54.
40. Orbai AM, Perin J, Gorlier C, Coates LC, Kiltz U, Leung YY, Palominos PE, Canete JD, Scivo R, Balanescu A, Dernis E, Talli S, Ruysse-Witrand A, Soubrier M, Aydin S, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, Smolen JS, de Wit M, Gossec L. Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. *Arthritis Care Res* 2020;72:1772-9.
41. Marzo-Ortega H, Mease PJ, Rahman P, Navarro-Compan V, Strand V, Dougados M, Combe B, Wei JCC, Baraliakos X, Hunter T, Sandoval D, Li XQ, Zhu BJ, Bessette L, Deodhar A. Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks. *Rheumatol Ther* 2020;7:759-74.
42. Maksymowych WP, Pedersen SJ, Weber U, Baraliakos X, Machado PM, Eshed I, de Hooge M, Sieper J, Wichuk S, Rudwaleit M, van der Heijde D, Landewe RBM, Poddubnyy D, Ostergaard M, Lambert RGW. Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. *Ann Rheum Dis* 2020;79:935-42.
43. Mai A, Krause D, Braun J, Starke RP. Is team-based rheumatological care with delegation to specialised nurses equal to or even superior to standard care?-the StarkeR project. *Z Rheumatol* 2020;79:52-4.
44. Mader R, Baraliakos X, Eshed I, Novofastovski I, Bieber A, Verlaan JJ, Kiefer D, Pappone N, Atzeni F. Imaging of diffuse idiopathic skeletal hyperostosis (DISH). *RMD Open* 2020;6:7.
45. Mader R, Baraliakos X, Eshed I, Novofastovski I, Bieber A, Verlaan JJ, Kiefer D, Pappone N, Atzeni F. Imaging of diffuse idiopathic skeletal hyperostosis (DISH) (vol 6, e001151, 2020). *RMD Open* 2020;6:1.
46. Mader R, Baraliakos X, Eshed I, Atzenis F. Imaging of diffuse idiopathic skeletal hyperostosis (DISH) (vol 6, e001151, 2020). *RMD Open* 2020;6:1.
47. Lorenz HM, Aringer M, Braun J, Hoyer BF, Krause A, Meyer-Olson D, Mucke J, Rudwaleit M, Schneider M, Sewerin P, Spathling-Mestekemper S, Specker C, Voormann A, Wagner U, Wendler J, Schulze-Koops H. Mission statement from rheumatologists in the German Society of Rheumatology (DGRh e.V.) We live rheumatology. *Z Rheumatol* 2020;79:1018-21.
48. Landewe RBM, van der Heijde D, Dougados M, Baraliakos X, Van den Bosch FE, Gaffney K, Bauer L, Hoepken B, Davies OR, de Peyrecave N, Thomas K, Gensler L. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. *Ann Rheum Dis* 2020;79:920-8.
49. Landewe R, van der Heijde D, Dougados M, Baraliakos X, van den Bosch F, Gaffney K, Bauer L, Hoepken B, de Peyrecave N, Thomas K, Gensler LS. Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE. *Rheumatol Ther* 2020;7:581-99.
50. Krause A, Schuch F, Braun J, Gauler G, Hoepfer K, Kruger K, Wallhauser M, Voormann AJ. Delegation of medical tasks in rheumatology. *Z Rheumatol* 2020;79:123-31.
51. Krause A, Kruger K, Braun J, Gauler G, Hoepfer K, Schuch F, Voormann AJ. Delegation of medical Services in Rheumatology. *Z Rheumatol* 2020;79:47-8.

52. Knitza J, Callhoff J, Chehab G, Hueber A, Kiltz U, Kleyer A, Krusche M, Simon D, Specker C, Schneider M, Voormann A, Welcker M, Richter JG. Position paper of the commission on digital rheumatology of the German Society of Rheumatology: tasks, targets and perspectives for a modern rheumatology. *Z Rheumatol* 2020;79:562-9.
53. Kiltz U, Wendling D, Braun J. ASAS Health Index: The "All in One" for Spondyloarthritis Evaluation? *J Rheumatol* 2020;47:1457-60.
54. Kiltz U, Spiller I, Sieper J, Braun J. Is it possible to delegate medical services to qualified nurses specialized in rheumatology when evaluating patients with suspicion of ankylosing spondylitis?-Results of the PredAS study. *Z Rheumatol* 2020;79:729-36.
55. Kiltz U, Sfrikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, Gullick N, Conrad C, Rigopoulos D, Lespessailles E, Romanelli M, Ghislain PD, Brandt-Jurgens J, Rashkov R, Aassi M, Orsenigo R, Perella C, Pournara E, Gathmann S, Jagiello P, Veit J, Augustin M. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study. *Adv Ther* 2020;37:2865-83.
56. Kiltz U, Landewe RBM, van der Heijde D, Rudwaleit M, Weisman MH, Akkoc N, Boonen A, Brandt J, Carron P, Dougados M, Gossec L, Jongkees M, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compan V, Niederman K, Sampaio-Barros PD, Slobodin G, van den Bosch FE, van Tubergen A, van Weely S, Wiek D, Braun J. Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. *Ann Rheum Dis* 2020;79:193-201.
57. Kiltz U, Kiefer D, Braun J, Schiffrin EJ, Girard-Guyonvarc'h C, Gabay C. Prolonged treatment with Tadekinig alfa in adult-onset Still's disease. *Ann Rheum Dis* 2020;79:2.
58. Kiltz U, Kiefer D, Boonen A. (Health-Related) Quality of Life as an Outcome in Studies of Axial Spondyloarthritis. *Rheum Dis Clin North Am* 2020;46:379-+.
59. Kiltz U, Celik A, Tsiami S, Baraliakos X, Andreica I, Kiefer D, Buhning B, Braun J. How well are patients with inflammatory rheumatic diseases protected against measles? *Z Rheumatol* 2020;79:912-21.
60. Kiltz U, Braun J. Assessments of Functioning in Patients With Axial Spondyloarthritis. *J Rheum Dis* 2020;27:22-9.
61. Kiltz U, Braun J. Current treatment of axial spondylarthritis Clinical efficacy. *Z Rheumatol* 2020;79:13-22.
62. Kiefer D, von Brunn M, Baraliakos X, Andreica I, Braun J. Clinical significance of determination of DFS70 antibodies to rule out connective tissue diseases. *Z Rheumatol* 2020;79:749-54.
63. Kiefer D, Baraliakos X, Buhning B, Kiltz U, Braun J. Epionics SPINE-use of an objective method to examine spinal mobility in patients with axial spondyloarthritis. *Z Rheumatol* 2020;79:143-52.
64. Kiefer D, Baraliakos X. EULAR points to consider: use of big data in rheumatic and musculoskeletal diseases. *Z Rheumatol* 2020;79:395-6.
65. Kiefer D, Andreica I, Braun J. Dermatomyositis associated with rapid progression of pulmonary involvement. *Dtsch Med Wochenschr* 2020;145:394-8.
66. Kerschbaumer A, Smolen JS, Dougados M, De Wit M, Primdahl J, McInnes I, van der Heijde D, Baraliakos X, Falzon L, Gossec L. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis* 2020;79:778-86.
67. Hebeisen M, Micheroli R, Scherer A, Baraliakos X, de Hooge M, van der Heijde D, Landewe R, Burki K, Nissen MJ, Moller B, Zufferey P, Exer P, Ciurea A. Spinal radiographic progression in axial spondyloarthritis and the

impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. *PLoS One* 2020;15:16.

68. Gossec L, Kedra J, Servy H, Pandit A, Stones S, Berenbaum F, Finckh A, Baraliakos X, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Burmester GR, Radstake T. EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases. *Ann Rheum Dis* 2020;79:69-76.
69. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, Primdahl J, McGonagle DG, Aletaha D, Balanescu A, Balint PV, Bertheussen H, Boehncke WH, Burmester GR, Canete JD, Damjanov NS, Kragstrup TW, Kvien TK, Landewe RBM, Lories RJU, Marzo-Ortega H, Poddubnyy D, Manica SAR, Schett G, Veale DJ, Van den Bosch FE, van der Heijde D, Smolen JS. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis* 2020;79:700-12.
70. Gossec L, Baraliakos X, Kerschbaumer A. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update (vol 79, 700, 2020). *Ann Rheum Dis* 2020;79:1.
71. Gerlich C, Andreica I, Kuffner R, Krause D, Lakomek HJ, Reusch A, Braun J. Evaluation of a basic educational program for patients with rheumatoid arthritis. *Z Rheumatol* 2020;79:737-48.
72. Gensler LS, Szumski A, Jones HE, Baraliakos X. Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype? *Clin Exp Rheumatol* 2020;38:329-32.
73. Gall S, Tsiami S, Braun J. Polymyalgic complaint: is there a tumor behind it? *Dtsch Med Wochenschr* 2020;145:1253-7.
74. Fruth M, Seggewiss A, Kozik J, Martin-Seidel P, Baraliakos X, Braun J. Diagnostic capability of contrast-enhanced pelvic girdle magnetic resonance imaging in polymyalgia rheumatica. *Rheumatology* 2020;59:2864-71.
75. Fiehn C, Baraliakos X, Edelmann E, Froschauer S, Feist E, Karberg K, Ruehlmann JM, Schuch F, Welcker M, Zinke S. Current state, goals and quality standards of outpatient care in rheumatology: position paper of the Professional Association of German Rheumatologists (BDRh). *Z Rheumatol* 2020;79:770-9.
76. Dougados M, Wei JCC, Landewe R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li XQ, Zhao FY, Bertram CC, Gallo G, Carlier H, Gensler LS, Grp C-VS, Grp C-WS. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). *Ann Rheum Dis* 2020;79:176-85.
77. Buehring B, Thomas J, Wittkamper T, Baraliakos X, Braun J. Evaluation of the trabecular bone score (TBS) in routine clinical care of patients with inflammatory rheumatic and non-inflammatory diseases. Correlation with conventional bone mineral density measurement and prevalence of vertebral fractures. *Z Rheumatol* 2020;79:1067-74.
78. Braun J, Tsiami S, Buehring B, Kiefer D, Andreica I, Baraliakos X, Kiltz U. Biosimilars and the nocebo effect. *Z Rheumatol* 2020;79:267-75.
79. Braun J, Kiltz U, Muller-Ladner U. Is complete immunity against measles a realistic target for patients with rheumatic diseases and how can it possibly be achieved? *Z Rheumatol* 2020;79:922-8.
80. Braun J, Kiltz U, Baraliakos X. Establishment of classification criteria for axial spondyloarthritis-how far is good for making diagnoses? *Z Rheumatol* 2020;79:132-4.
81. Braun J, Buehring B, Vorstand D. Obituary of the German Society for Rheumatology for Prof. Dieter Felsenberg. *Z Rheumatol* 2020;79:826-7.

82. Braun J, Baraliakos X, Westhoff T. Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication. *Semin Arthritis Rheum* 2020;50:285-8.
83. Braun J, Baraliakos X, Kiltz U, Kruger K, Burmester GR, Wassenberg S, Thomas MH. Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis. *J Rheumatol* 2020;47:35-41.
84. Braun J, Baraliakos X. Do NSAIDs affect radiographic progression in axial SpA? *Nat Rev Rheumatol* 2020;16:9-10.
85. Braun J. Axial spondyloarthritis and psoriatic arthritis Current results and assessments. *Z Rheumatol* 2020;79:1-4.
86. Baraliakos X, Weisman MH. Spondyloarthritis: The Changing Landscape-Are We There Yet? Preface. *Rheum Dis Clin North Am* 2020;46:XIII-XIV.
87. Baraliakos X, Tsiami S, Redeker I, Tsimopoulos K, Marashi A, Ruetten S, Fedorov K, Avram A, Morzeck D, Fruth M, Braun J. Early recognition of patients with axial spondyloarthritis - evaluation of referral strategies in primary care. *Rheumatology* 2020;59:3845-52.
88. Baraliakos X, Sewerin P, de Miguel E, Pournara E, Kleinmond C, Wiedon A, Behrens F. Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial. *BMC Musculoskelet Disord* 2020;21:7.
89. Baraliakos X, Richter A, Feldmann D, Ott A, Buelow R, Schmidt CO, Braun J. Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged < 45 years. *Ann Rheum Dis* 2020;79:186-92.
90. Baraliakos X, Ostergaard M, Gensler LS, Poddubnyy D, Lee EY, Kiltz U, Martin R, Sawata H, Readie A, Porter B, the SSG. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS). *Clin Drug Invest* 2020;40:269-78.
91. Baraliakos X, Kleyer A, Simon D, Kohm M, Ohrndorf S, Sewerin P. Imaging of psoriatic arthritis and aspects of radiographic progression. *Z Rheumatol* 2020;79:40-52.
92. Baraliakos X, Hermann KGA, Xu S, Hsia EC, Braun J. Spinal mobility in the cervical and lumbar spine correlates with magnetic resonance imaging findings for inflammatory and structural changes in patients with active ankylosing spondylitis. *Clin Exp Rheumatol* 2020;38:467-71.
93. Baraliakos X, Gensler LS, D'Angelo S, Iannone F, Favalli EG, de Peyrecave N, Auteri SE, Caporali R. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. *Ther Adv Musculoskelet Dis* 2020;12:17.
94. Baraliakos X, Braun J. Imaging in patients with axial spondylarthritis with focus on new bone formation. *Z Rheumatol* 2020;79:33-9.
95. Baraliakos X. Imaging Atlas of Axial Spondyloarthritis. *J Rheumatol* 2020;47:1454-.
96. Aouad K, Ziade N, Baraliakos X. Structural progression in axial spondyloarthritis. *Joint Bone Spine* 2020;87:131-6.
97. Aouad K, Maksymowych WP, Baraliakos X, Ziade N. Update of imaging in the diagnosis and management of axial spondyloarthritis. *Best Pract Res Clin Rheumatol* 2020;34:23.

98. Andraesen RA, Kristensen LE, Baraliakos X, Strand V, Mease PJ, de Wit M, Ellingsen T, Hansen IMJ, Kirkham J, Wells GA, Tugwell P, Maxwell L, Boers M, Egstrup K, Christensen R. Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. *Arthritis Res Ther* 2020;22:16.
99. Ali Y, Abutiban F, Alawadhi A, AlDei A, Alenizi A, Alhajeri H, Al-Herz A, Alkandari W, Dehrab A, Hasan E, Hayat S, Ghanem A, Saleh K, Baraliakos X. Recommendation for the Management of Spondyloarthritis Patients in Kuwait. *Open Access Rheumatol* 2020;12:147-65.
100. Abrar DB, Schleich C, Tsiami S, Muller-Lutz A, Radke KL, Holthausen N, Frenken M, Boschheidgen M, Antoch G, Mucke J, Sewerin P, Braun J, Nebelung S, Baraliakos X. Functional MR imaging beyond structure and inflammation-radiographic axial spondyloarthritis is associated with proteoglycan depletion of the lumbar spine. *Arthritis Res Ther* 2020;22:9.
101. Ziade NR, Mallak I, Merheb G, Ghorra P, Baerlecken N, Witte T, Baraliakos X. Added Value of Anti-CD74 Autoantibodies in Axial SpondyloArthritis in a Population With Low HLA-B27 Prevalence. *Front Immunol* 2019;10:6.
102. Ziade NR, Baraliakos X. Tapering bDMARDs in axial SpA - what is the current evidence? *Nat Rev Rheumatol* 2019;15:322-4.
103. Ziade N, Karam GA, Merheb G, Mallak I, Irani L, Alam E, Messaykeh J, Menassa J, Mroue K, Uthman I, Masri AF, Ghorra P, Witte T, Baraliakos X. HLA-B27 prevalence in axial spondyloarthritis patients and in blood donors in a Lebanese population: Results from a nationwide study. *Int J Rheum Dis* 2019;22:708-14.
104. van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landewe R, Richards HB, Porter B, Readie A. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. *Rheumatology* 2019;58:388-400.
105. Van den Bosch F, Flipo RM, Braun J, Vastesaeger N, Kachroo S, Govoni M. Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: the QUO-VADIS study. *Clin Exp Rheumatol* 2019;37:199-207.
106. Tsiami S, Regel A, Baraliakos X, Braun J, Kiltz U. Multi-Faceted Symptoms with Joint Pain, Exanthema and Eye Involvement. *Dtsch Med Wochenschr* 2019;144:759-63.
107. Sieper J, Braun J. Management: Medical and Non-medical Therapy of Axial Spondyloarthritis. *Aktuelle Rheumatol* 2019;44:345-51.
108. Ruetten S, Hahn P, Oezdemir S, Baraliakos X, Godolias G, Komp M. Full-endoscopic uniportal retropharyngeal odontoidectomy for anterior craniocervical infection. *Minim Invasive Ther Allied Technol* 2019;28:178-85.
109. Ruetten S, Baraliakos X, Godolias G, Komp M. Surgical treatment of anterior cervical osteophytes causing dysphagia. *J Orthop Surg* 2019;27:9.
110. Riechers E, Baerlecken N, Baraliakos X, Bakhsh KAM, Aries P, Bannert B, Becker K, Brandt-Jurgens J, Braun J, Ehrenstein B, Euler HH, Fleck M, Hein R, Karberg K, Kohler L, Matthias T, Max R, Melzer A, Meyer-Olson D, Rech J, Rockwitz K, Rudwaleit M, Schmidt RE, Schweikhard E, Sieper J, Stille C, von Hinuber U, Wagener P, Weidemann HF, Zinke S, Witte T. Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol* 2019;71:729-35.
111. Richter JG, Chehab G, Kiltz U, Callhoff J, Voormann A, Lorenz HM, Schneider M, Specker C. Digital health in Rheumatology- Status Survey 2018/19 (vol 144, pg 464, 2019). *Dtsch Med Wochenschr* 2019;144:E3-E.



112. Richter JG, Chehab G, Kiltz U, Callhoff J, Voormann A, Lorenz HM, Schneider M, Specker C. Digital Health in the Rheumatology - Status Survey 2018/19. *Dtsch Med Wochenschr* 2019;144:464-9.
113. Nikiphorou E, Baraliakos X. Treat to Target in Axial Spondyloarthritis. *Rheum Dis Clin North Am* 2019;45:519-+.
114. Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JCC, Hunter T, Gallo G, Sandoval D, Zhao FY, Dong Y, Bolce R, Marzo-Ortega H. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. *Rheumatol Ther* 2019;6:435-50.
115. Mandl P, Ciechomska A, Terslev L, Baraliakos X, Conaghan PG, D'Agostino MA, Iagnocco A, van der Laken CJ, Ostergaard M, Naredo E. Implementation and role of modern musculoskeletal imaging in rheumatological practice in member countries of EULAR. *RMD Open* 2019;5:6.
116. Maksymowych WP, Lambert RGW, Ostergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, Braun J, Burgos-Vargas R, de Hooge M, Deodhar AA, Eshed I, Jurik AG, Hermann KGA, Landewe RBM, Marzo-Ortega H, Navarro-Compan V, Poddubnyy D, Reijnierse M, Rudwaleit M, Sieper J, Van den Bosch FE, Van der Heijde D, van der Horst-Bruinsma IE, Wichuk S, Baraliakos X. MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. *Ann Rheum Dis* 2019;78:1550-8.
117. Mai A, Braun J, Reese JP, Westerhoff B, Trampisch US, Klaassen-Mielke R, Timmesfeld N, Trampisch HJ, Krause D. Nurse-led care versus physician-led care in the management of rheumatoid arthritis and psoriatic arthritis (StaerkeR): study protocol for a multi-center randomized controlled trial. *Trials* 2019;20:8.
118. Kwan YH, Aw FF, Fong W, Phang JK, Kiltz U, Lim KK, Chew EH, Lui NL, Tan CS, Thumboo J, Ostbye T, Leung YY. Validity and reliability of the Assessment of Spondyloarthritis International Society Health Index in English-speaking patients with axial spondyloarthritis in Singapore. *Int J Rheum Dis* 2019;22:1644-51.
119. Kiltz U, Winter J, Schirmer M, Baraliakos X, Braun J. Validation of the German translation of the ASAS health index. A questionnaire to assess functioning and health in patients with spondyloarthritis. *Z Rheumatol* 2019;78:352-8.
120. Kiltz U, Tsiami S, Kiefer D, Baraliakos X, Buhning B, Braun J. Assessment and Outcome Parameters in Patients with Axial Spondyloarthritis. *Aktuelle Rheumatol* 2019;44:332-8.
121. Kiltz U, Braun J, Becker A, Chenot JF, Dreimann M, Hammel L, Heiligenhaus A, Hermann KG, Klett R, Krause D, Kreitner KF, Lange U, Lauterbach A, Mau W, Mossner R, Oberschelp U, Philipp S, Pleyer U, Rudwaleit M, Schneider E, Schulte TL, Sieper J, Stallmach A, Swoboda B, Winking M. Long Version on the S3 Guidelines for Axial Spondyloarthritis including Bechterews Disease and early Forms, Update 2019 Evidence-based Guidelines of the German Society for Rheumatology (DGRh) and participating Medical Scientific Specialist Societies and other Organizations. *Z Rheumatol* 2019;78:S3-S64.
122. Kiltz U, Braun J. S3 Guidelines for Axial Spondyloarthritis including Bechterews Disease and early Forms Update 2019. *Z Rheumatol* 2019;78:S1-S2.
123. Kiefer D, Kiltz U, Braun J. Chronic Back Pain, Cervicothoracic Myelopathy and weight loss - a case report of an IgG4-related disease. *Dtsch Med Wochenschr* 2019;144:965-8.
124. Kiefer D, Baraliakos X, Buhning B, Kiltz U, Braun J. Epionics SPINE - Use of an objective Method to Examine Spinalmobility in Patients with axial Spondyloarthritis (pg 1, 2019). *Z Rheumatol* 2019;78:773-4.
125. Kiefer D, Baraliakos X. Imaging in Axial Spondyloarthritis - Challenges and Limitations. *Aktuelle Rheumatol* 2019;44:321-31.

126. Kedra J, Radstake T, Pandit A, Baraliakos X, Berenbaum F, Finckh A, Fautrel B, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Servy H, Stones S, Burmester G, Gossec L. Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations. *RMD Open* 2019;5:8.
127. Kallinich T, Blank N, Braun T, Feist E, Kiltz U, Neudorf U, Oommen PT, Weseloh C, Wittkowski H, Braun J. Evidence-based treatment recommendations for familial Mediterranean fever. A joint statement by the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology. *Z Rheumatol* 2019;78:91-101.
128. Gorlier C, Orbai AM, Puyraimond-Zemmour D, Coates LC, Kiltz U, Leung YY, Palominos P, Canete JD, Scrivo R, Balanescu A, Dernis E, Talli S, Ruysse-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, de Wit M, Smolen JS, Gossec L. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. *Ann Rheum Dis* 2019;78:201-8.
129. Gladman DD, Orbai AM, Klitz U, Wei JCC, Gallo G, Birt J, Rathmann S, Shrom D, Marzo-Ortega H. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. *Arthritis Res Ther* 2019;21:9.
130. Essers I, Hilgsmann M, Kiltz U, Bansback N, Braun J, van Der Heijde D, Boonen A. Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI. *RMD Open* 2019;5:9.
131. Edelmann E, Lakomek HJ, Bessler F, Braun J, Froschauer S, Hellmich B, von Hinuber U, Kalthoff L, Karberg K, Kekow J, Krause A, Muller-Brodmann W, Munte A, Ruehlmann JM, Zinke S. Outpatient specialist medical treatment (ASV)-a new treatment level in rheumatology. *Z Rheumatol* 2019;78:765-73.
132. Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Gupta AD, Widmer A, Pricop L, Fox T. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. *Arthritis Res Ther* 2019;21:11.
133. Choy E, Baraliakos X, Behrens F, D'Angelo S, de Vlam K, Kirkham BW, Ostergaard M, Schett GA, Rissler M, Chaouche-Teyara K, Perella C. The need for comparative data in spondyloarthritis. *Arthritis Res Ther* 2019;21:6.
134. Carli L, Calabresi E, Governato G, Braun J. One year in review 2018: axial spondyloarthritis. *Clin Exp Rheumatol* 2019;37:889-98.
135. Braun J, Schwarting A, Hammel L, Legeler C, Wimmer P, Farber L, Behrens F. Medical care situation of patients with ankylosing spondylitis and psoriatic arthritis in Germany. Medical care situation of patients with spondyloarthritis (SpA): ankylosing spondylitis (AS) and psoriatic arthritis (PsA) from the perspective of rheumatologists in private practice and hospitals in Germany-Results of the research project "SpA Loop-Life of Outpatients". *Z Rheumatol* 2019;78:372-81.
136. Braun J, Mosch T, Fischer I, Kiltz U. Identification of patients with axial spondylarthritis in primary care (AWARE study). *Z Rheumatol* 2019;78:568-76.
137. Braun J, Kiltz U, Baraliakos X. Observation by magnetic resonance imaging of sacroiliac joint ankylosis in young spondyloarthritis patients receiving biologic therapy: comment on the article by Bray et al. *Arthritis Rheumatol* 2019;71:2128-9.

138. Braun J, Kiltz U, Andreica I, Buehring B, Guminski B, Hausler U, Kavruk H, Kiefer D, Lochowski R, Mintrop B, Baraliakos X. Rheumatological care in the Rheumazentrum Ruhrgebiet Rheumatism Center-a model for conurbations. *Z Rheumatol* 2019;78:753-64.
139. Braun J, Kiltz U. What's new on Gout? Reports from the ACR 2018. *Z Rheumatol* 2019;78:540-9.
140. Braun J, Haibel H, de Hooge M, Landewe R, Rudwaleit M, Fox T, Readie A, Richards HB, Porter B, Martin R, Poddubnyy D, Sieper J, van der Heijde D. Spinal radiographic progression over 2years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. *Arthritis Res Ther* 2019;21:8.
141. Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, Talloczy Z, Porter B. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. *Rheumatology* 2019;58:859-68.
142. Braun J, Baraliakos X, Buehring B, Fruth M, Kiltz U. Differential diagnosis of axial spondyloarthritis-axSpA mimics. *Z Rheumatol* 2019;78:31-42.
143. Braun J, Baraliakos X. Active and chronic sacroiliitis, spondylitis and enthesitis, How specific are imaging findings for axial spondyloarthritis? *Rheumatology* 2019;58:1321-4.
144. Braun J. Using combinations of biomarkers to understand inflammation and bone formation in axial spondyloarthritis - is anything better than CRP? *Rheumatology* 2019;58:1517-9.
145. Benesova K, Lorenz HM, Lion V, Voigt A, Krause A, Sander O, Schneider M, Feuchtenberger M, Nigg A, Leipe J, Briem S, Tiessen E, Haas F, Rihl M, Meyer-Olson D, Baraliakos X, Braun J, Schwarting A, Dreher M, Witte T, Assmann G, Hoepfer K, Schmidt RE, Bartz-Bazzanella P, Gaubitz M, Specker C. Early recognition and screening consultation: a necessary way to improve early detection and treatment in rheumatology? Overview of the early recognition and screening consultation models for rheumatic and musculoskeletal diseases in Germany. *Z Rheumatol* 2019;78:722-42.
146. Baraliakos X, Szumski A, Koenig AS, Jones H. The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. *Semin Arthritis Rheum* 2019;48:997-1004.
147. Baraliakos X, Hoffmann F, Deng XH, Wang YY, Huang F, Braun J. Detection of Erosions in Sacroiliac Joints of Patients with Axial Spondyloarthritis Using the Magnetic Resonance Imaging Volumetric Interpolated Breath-hold Examination. *J Rheumatol* 2019;46:1445-9.
148. Baraliakos X, Conaghan PG, D'Agostino MA, Maksymowych W, Naredo E, Ostergaard M, Schett G, Emery P. Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities. *Eur J Rheumatol* 2019;6:38-47.
149. Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A, Grp MS. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. *RMD Open* 2019;5:8.
150. Baraliakos X, Boehm H, Bahrami R, Samir A, Schett G, Lubner M, Ramming A, Braun J. What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis. *Ann Rheum Dis* 2019;78:1220-5.
151. Baraliakos X, Anderson JK. Reply to: Bone marrow oedema on sacroiliac/spine MRI: is it really a sign of objective inflammation warranting treatment? *Clin Exp Rheumatol* 2019;37:S11-S2.

152. Andreoli L, Ovseiko PV, Hassan N, Kiltz U, van Mens L, Gossec L, Coates LC. Gender equity in clinical practice, research and training: Where do we stand in rheumatology? *Joint Bone Spine* 2019;86:669-72.
153. Andreasen RA, Kristensen LE, Egstrup K, Baraliakos X, Strand V, Horn HC, Hansen IMJ, Christensen R, Ellingsen T. The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study. *Arthritis Res Ther* 2019;21:11.
154. Webers C, Essers I, van Tubergen A, Braun J, Heldmann F, Baraliakos X, Boonen A. Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach. *Arthritis Care Res* 2018;70:608-16.
155. Weber U, Baraliakos X. Imaging in axial spondyloarthritis: Changing concepts and thresholds. *Best Pract Res Clin Rheumatol* 2018;32:342-56.
156. van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh AF. Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. *RMD Open* 2018;4:11.
157. van der Heijde D, Baraliakos X, Hermann KGA, Landewe RBM, Machado PM, Maksymowych WP, Davies OR, de Peyrecave N, Hoepken B, Bauer L, Nurminen T, Braun J. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. *Ann Rheum Dis* 2018;77:699-705.
158. van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, Abi-Saab W, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Mozaffarian N, Liu K, Greer JM, Deodhar A, Landewe R. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. *Lancet* 2018;392:2378-87.
159. Syrbe U, Baraliakos X. Spondyloarthritis. *Z Rheumatol* 2018;77:783-8.
160. Smolen JS, Schoels M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewe R, Mease P, Sieper J, Stamm T, de Wit M, Aletaha D, Baraliakos X, Betteridge N, van den Bosch F, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, de Vlam K, van der Heijde D. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis* 2018;77:3-17.
161. Sawicki LM, Lutje S, Baraliakos X, Braun J, Kirchner J, Boos J, Heusch P, Ruhlmann V, Herrmann K, Umutlu L, Quick HH, Antoch G, Buchbender C. Dual-phase hybrid F-18-Fluoride Positron emission tomography/MRI in ankylosing spondylitis: Investigating the link between MRI bone changes, regional hyperaemia and increased osteoblastic activity. *J Med Imag Radiat Oncol* 2018;62:313-9.
162. Ruetten S, Hahn P, Oezdemir S, Baraliakos X, Merk H, Godolias G, Komp M. Full-endoscopic Uniportal Odontoidectomy and Decompression of the Anterior Cervicomedullary Junction Using the Retropharyngeal Approach. *Spine* 2018;43:E911-E8.
163. Ruetten S, Hahn P, Oezdemir S, Baraliakos X, Merk H, Godolias G, Komp M. Full-endoscopic uniportal decompression in disc herniations and stenosis of the thoracic spine using the interlaminar, extraforaminal, or transthoracic retropleural approach. *J Neurosurg-Spine* 2018;29:157-68.
164. Ruetten S, Hahn P, Oezdemir S, Baraliakos X, Merk H, Godolias G, Komp M. The full-endoscopic uniportal technique for decompression of the anterior craniocervical junction using the retropharyngeal approach: an anatomical feasibility study in human cadavers and review of the literature. *J Neurosurg-Spine* 2018;29:615-21.

165. Ruetten S, Hahn P, Oezdemir S, Baraliakos X, Godolias G, Komp M. Surgical treatment of cervical subaxial intraspinal extradural cysts using a full-endoscopic uniportal posterior approach. *J Orthop Surg* 2018;26:6.
166. Ruetten S, Hahn P, Oezdemir S, Baraliakos X, Godolias G, Komp M. Operation of Soft or Calcified Thoracic Disc Herniations in the Full-Endoscopic Uniportal Extraforaminal Technique. *Pain Physician* 2018;21:E331-E40.
167. Ruetten S, Hahn P, Oezdemir S, Baraliakos X, Godolias G, Komp M. Decompression of the anterior thoracic spinal canal using a novel full-endoscopic uniportal transthoracic retropleural technique: an anatomical feasibility study in human cadavers. *Clin Anat* 2018;31:716-23.
168. Poddubnyy D, Callhoff J, Spiller I, Listing J, Braun J, Sieber J, Rudwaleit M. Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care. *RMD Open* 2018;4:8.
169. Osthoff AKR, Niedermann K, Braun J, Adams J, Brodin N, Dagfinrud H, Duruoz T, Esbensen BA, Gunther KP, Hurkmans E, Juhl CB, Kennedy N, Kiltz U, Knittle K, Nurmohamed M, Pais S, Severijns G, Swinnen TW, Pitsillidou IA, Warburton L, Yankov Z, Vlieland T. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. *Ann Rheum Dis* 2018;77:1251-60.
170. Osthoff AKR, Juhl CB, Knittle K, Dagfinrud H, Hurkmans E, Braun J, Schoones J, Vlieland T, Niedermann K. Effects of exercise and physical activity promotion: meta-analysis informing the 2018 EULAR recommendations for physical activity in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis. *RMD Open* 2018;4:11.
171. Molto A, Gossec L, Meghnathi B, Landewe RBM, van der Heijde D, Atagunduz P, Elzorkany BK, Akkoc N, Kiltz U, Gu JR, Wei JCC, Dougados M, Grp A-FS. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. *Ann Rheum Dis* 2018;77:124-7.
172. Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewe RBM, van der Heijde D, Ciurea A, Rheumatologists Swiss C. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. *Ann Rheum Dis* 2018;77:63-9.
173. Maksymowych WP, van der Heijde D, Baraliakos X, Deodhar A, Sherlock SP, Li D, Fleishaker D, Hendriks T, Kanik KS. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. *Rheumatology* 2018;57:1390-9.
174. Landewe R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, Marzo-Ortega H, Magrey M, Kiltz U, Wang X, Li M, Zhong S, Mostafa NM, Lertratanakul A, Pangan AL, Anderson JK. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. *Lancet* 2018;392:134-44.
175. Kiltz U, van der Heijde D, Boonen A, Akkoc N, Bautista-Molano W, Burgos-Vargas R, Wei JCC, Chiowchanwisawakit P, Dougados M, Duruoz MT, Elzorkany BK, Gaydukova I, Gensler LS, Gilio M, Grazio S, Gu J, Inman RD, Kim TJ, Navarro-Compan V, Marzo-Ortega H, Ozgocmen S, dos Santos FP, Schirmer M, Stebbings S, van den Bosch FE, van Tubergen A, Braun J. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. *Ann Rheum Dis* 2018;77:1311-7.
176. Kiltz U, Baraliakos X, Buehring B, Braun J. Becoming older with axial spondyloarthritis. *Z Rheumatol* 2018;77:363-8.
177. Khmelinskii N, Regel A, Baraliakos X. The Role of Imaging in Diagnosing Axial Spondyloarthritis. *Front Med* 2018;5:11.

178. Fruth M, Buehring B, Baraliakos X, Braun J. Use of contrast-enhanced magnetic resonance imaging of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumatica. *Clin Exp Rheumatol* 2018;36:S86-S95.
179. Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Muller-Ladner U, Nothacker M, Nusslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Kruger K. S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs. *Z Rheumatol* 2018;77:S35-S53.
180. Deodhar A, Miossec P, Baraliakos X. Is undifferentiated spondyloarthritis a discrete entity? A debate. *Autoimmun Rev* 2018;17:29-32.
181. de Koning A, de Bruin F, van den Berg R, Ramiro S, Baraliakos X, Braun J, van Gaalen FA, Reijnierse M, van der Heijde D. Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. *Ann Rheum Dis* 2018;77:293-9.
182. de Bruin F, de Koning A, van den Berg R, Baraliakos X, Braun J, Ramiro S, van Gaalen FA, Reijnierse M, van der Heijde D. Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. *Ann Rheum Dis* 2018;77:371-7.
183. Carey JJ, Buehring B. Current imaging techniques in osteoporosis. *Clin Exp Rheumatol* 2018;36:S115-S26.
184. Buttgereit F, Brabant T, Dinges H, Hiemer I, Kaplani M, Kiltz U, Kyburz D, Reissbauer A, Schneider M, Weseloh C, Dejaco C. S3 guidelines on treatment of polymyalgia rheumatica. Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (OGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations. *Z Rheumatol* 2018;77:429-41.
185. Braun J, Lorenz HM, Muller-Ladner U, Schneider M, Schulze-Koops H, Specker C, Strangfeld A, Wagner U, Dorner T. Revised Version of the Statement by the DGRh on Biosimilars - Update 2017. *Z Rheumatol* 2018;77:81-90.
186. Braun J, Krause D. Structured Delegation of Physician Services as Part of a Concept Based Cooperation for the Management of Inflammatory Rheumatic Diseases'. *Aktuelle Rheumatol* 2018;43:410-1.
187. Braun J, Kiltz U. New Aspects on Gout The Information from the ACR-Congress 2017. *Z Rheumatol* 2018;77:1-6.
188. Braun J, Deodhar A, Landewe R, Baraliakos X, Miceli-Richard C, Sieper J, Quebe-Fehling E, Martin R, Porter B, Gandhi KK, van der Heijde D, Gallagher J, Maity N, Pillai N, Grp MS, Grp MS. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. *RMD Open* 2018;4:9.
189. Braun J, Baraliakos X, Kiltz U, Schmitz-Bortz E, Kalthoff L, Krause D. Research Networks - Rheumatism Research Group Ruhr. *Z Rheumatol* 2018;77:31-3.
190. Braun J, Baraliakos X, Fruth M. The role of 18F-FDG positron emission tomography for the diagnosis of vasculitides. *Clin Exp Rheumatol* 2018;36:S108-S14.
191. Braun J, Baraliakos X, Buehring B, Kiltz U, Fruth M. Imaging of axial spondyloarthritis. New aspects and differential diagnoses. *Clin Exp Rheumatol* 2018;36:S35-S42.

192. Braun J. Discontinuing tumour necrosis factor inhibitors in non-radiographic axial spondyloarthritis. *Lancet* 2018;392:98-100.
193. Braun J. Axial spondyloarthritis including ankylosing spondylitis. *Rheumatology* 2018;57:1-3.
194. Bautista-Molano W, Landewe RBM, Kiltz U, Valle-Onate R, van der Heijde D. Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis. *Clin Rheumatol* 2018;37:3063-8.
195. Baraliakos X, Regel A, Kiltz U, Menne HJ, Dybowski F, Igelmann M, Kalthoff L, Krause D, Saracbası-Zender E, Schmitz-Bortz E, Braun J. Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. *Rheumatology* 2018;57:1541-7.
196. Baraliakos X, Kivitz J, Deodhar AA, Braun J, Wei JC, Delicha EM, Talloczy Z, Porter B, Grp MS. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. *Clin Exp Rheumatol* 2018;36:50-5.
197. Baraliakos X, Braun J. Learning from the youngsters: ixekizumab in active ankylosing spondylitis. *Lancet* 2018;392:2415-6.
198. Baraliakos X, Berenbaum F, Favalli EG, Olivieri I, Ostendorf B, Poddubnyy D, De Vlam K. Challenges and Advances in Targeting Remission in Axial Spondyloarthritis. *J Rheumatol* 2018;45:153-7.
199. Alunno A, Carubbi F, Stones S, Gerli R, Giacomelli R, Baraliakos X. The Impact of Fibromyalgia in Spondyloarthritis: From Classification Criteria to Outcome Measures. *Front Med* 2018;5:8.
200. Zink A, Braun J, Gromnica-Ihle E, Krause D, Lakomek HJ, Mau W, Muller-Ladner U, Rautenstrauch J, Specker C, Schneider M. Memorandum of the German Society for Rheumatology on the quality of treatment in rheumatology - Update 2016. *Z Rheumatol* 2017;76:195-207.
201. Witte T, Baraliakos X. Magnetic resonance imaging (MRI) diagnostics in axial spondyloarthritis. *Z Rheumatol* 2017;76:574-9.
202. Wilburn J, McKenna SP, Kutlay A, Bender T, Braun J, Castillo-Gallego C, Favero M, Geher P, Kiltz U, Martin-Mola E, Ramonda R, Rouse M, Tennant A, Kucukdeveci AA. Adaptation of the osteoarthritis-specific quality of life scale (the OAQoL) for use in Germany, Hungary, Italy, Spain and Turkey. *Rheumatol Int* 2017;37:727-34.
203. Wand K, Brinkmann F, Rothoef T, Trobs RB, Kececioglu D, Sandica E, Lucke T, Heyer CM, Lochowski R, Koerner-Rettberg C, Rossler L. Pulmonary Arteriel Microembolism As an Initial Manifestation of Behcets Disease. *Monschr Kinderheilkd* 2017;165:427-32.
204. van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Geher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compan V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis* 2017;76:978-91.
205. van der Heijde D, Dougados M, Landewe R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. *Rheumatology* 2017;56:1498-509.
206. Uceyler N, Burgmer M, Friedel E, Greiner W, Petzke F, Sarholz M, Schiltenswolf M, Winkelmann A, Sommer C, Hauser W. Etiology and pathophysiology of fibromyalgia syndrome. Updated guidelines 2017, overview of

systematic review articles and overview of studies on small fiber neuropathy in FMS subgroups. *Schmerz* 2017;31:239-45.

207. Sepriano A, Regel A, van der Heijde D, Braun J, Baraliakos X, Landewe R, Van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. *RMD Open* 2017;3:12.

208. Schiltenswolf M, Eidmann U, Kollner V, Kuhn T, Offenbacher M, Petzke F, Sarholz M, Weigl M, Wolf B, Hauser W. Multimodal therapy of fibromyalgia syndrome. Updated guidelines 2017 and overview of systematic review articles. *Schmerz* 2017;31:285-8.

209. Reusch A, Musekamp G, Kuffner R, Dorn M, Braun J, Ehlebracht-Konig I. Evaluation of effectiveness of education in rheumatology Recommendations according to a patient education model. *Z Rheumatol* 2017;76:613-21.

210. Regel A, Sepriano A, Baraliakos X, van der Heijde D, Braun J, Landewe R, Van den Bosch F, Falzon L, Ramiro S. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. *RMD Open* 2017;3:11.

211. Regel A, Sepriano A, Baraliakos X. Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/ELILAR recommendations for the management of axial spondyloarthritis (vol 3, e000397corr1, 2017). *RMD Open* 2017;3:1.

212. Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Urena S, Mikazane H, Lee YA, Smiyan S, Lim MJ, Kadinov V, Abud-Mendoza C, Kim H, Lee SJ, Bae Y, Kim S, Braun J. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. *Ann Rheum Dis* 2017;76:346-54.

213. Mader R, Verlaan JJ, Eshed I, Jacome BA, Puttini PS, Atzeni F, Buskila D, Reinshtein E, Novofastovski I, Fawaz A, Kurt DV, Baraliakos X. Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next. *RMD Open* 2017;3:6.

214. Laloo F, Herregods N, Varkas G, Jaremko JL, Baraliakos X, Elewaut D, Van den Bosch F, Verstraete K, Jans L. MR signal in the sacroiliac joint space in spondyloarthritis: a new sign. *Eur Radiol* 2017;27:2024-30.

215. Krause C, Herborn G, Braun J, Rudolf H, Wassenberg S, Rau R, Krause D. Response to methotrexate predicts long-term mortality of patients with rheumatoid arthritis independent of the degree of response: results of a re-evaluation 30 years after baseline. *Clin Exp Rheumatol* 2017;35:384-9.

216. Kollner V, Bernardy K, Greiner W, Krumbein L, Lucius H, Offenbacher M, Sarholz M, Settan M, Hauser W. Psychotherapy and psychological procedures for fibromyalgia syndrome. Updated guidelines 2017 and overview of systematic review articles. *Schmerz* 2017;31:266-72.

217. Kiltz U, von Zabern C, Baraliakos X, Heldmann F, Mintrop B, Sarholz M, Krause D, Dybowski F, Kalthoff L, Braun J. Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study. *Arthritis Res Ther* 2017;19:9.

218. Kiltz U, Smolen J, Bardin T, Solal AC, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, Perez-Ruiz F, Castelar-Pinheiro GDR, Saag K, So A, Mellado JV, Weisman M, Westhoff TH, Yamanaka H, Braun J. Treat-to-target (T2T) recommendations for gout. *Ann Rheum Dis* 2017;76:7.



219. Kiltz U, Rudwaleit M, Sieper J, Braun J. Evidence-Based Recommendations on Diagnostics and Therapy of axial Spondyloarthritis S3-Guidelines of the German Society for Rheumatology (DGRh) in Cooperation with the Association of the Scientific Medical Societies in Germany (AWMF). *Z Rheumatol* 2017;76:111-7.
220. Kiltz U, Baraliakos X, Regel A, Buhning B, Braun J. Causes of pain in patients with axial spondyloarthritis. *Clin Exp Rheumatol* 2017;35:S102-S7.
221. Kiltz U, Alten R, Fleck M, Kruger K, Manger B, Nuesslein H, Reuss-Borst M, Schwarting A, Schulze-Koops H, Tausche AK, Braun J, Muller-Ladner U. Evidence-based Recommendations for Diagnostics and Treatment of Gouty Arthritis in the specialist Sector S2e-Guidelines of the German Society of Rheumatology (DGRh) in Cooperation with the AWMF. *Z Rheumatol* 2017;76:118-24.
222. Herregods N, Dehoorne J, Van den Bosch F, Jaremko JL, Van Vlaenderen J, Joos R, Baraliakos X, Varkas G, Verstraete K, Elewaut D, Jans L. ASAS definition for sacroiliitis on MRI in SpA: applicable to children? *Pediatr Rheumatol* 2017;15:10.
223. Gueudry J, Thorne JE, Bansie R, Braun J, van Hagen PM, Bodaghi B. Biologic Therapy for HLA-B27-associated Ocular Disorders. *Ocul Immunol Inflamm* 2017;25:169-78.
224. Gudu T, Kiltz U, de Wit M, Kvien TK, Gossec L. Mapping the Effect of Psoriatic Arthritis Using the International Classification of Functioning, Disability and Health. *J Rheumatol* 2017;44:193-200.
225. Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Lenaerts J, van den Bosch F, Wei JCC, Pedersen R, Bonin R, Jones H, Marshall L, Logeart I, Vlahos B, Bukowski JF, Maksymowych WP. Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study. *Arthritis Care Res* 2017;69:1590-8.
226. Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, Heiberg T, Helliwell PS, Kalyoncu U, Kvien TK, Kiltz U, Niedermayer D, Otsa K, Scivo R, Smolen J, Stamm TA, Veale DJ, de Vlam K, de Wit M, Gossec L. Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. *Arthritis Care Res* 2017;69:1606-11.
227. Cruz EB, Ramiro S, Machado P, Sousa S, Aguiar R, Sepriano A, Rodrigues-Manica S, Kiltz U, Branco JC, Pimentel-Santos FM. Translation and cross-cultural adaptation of the ASAS Health Index and ASAS environmental factors item set into European Portuguese language. *Acta Reumatol Port* 2017;42:256-62.
228. Braun J, Sieper J. Low Rate of Progression to Ankylosing Spondylitis Among Patients With Presumed Nonradiographic Axial Spondyloarthritis: Comment on the Article by Wang et al. *Arthritis Rheumatol* 2017;69:676-7.
229. Braun J, Kruger K, Manger B, Schneider M, Specker C, Trappe HJ. Cardiovascular comorbidity in inflammatory rheumatological conditions. *Dtsch Arztebl Int* 2017;114:197-I.
230. Braun J, Kiltz U. How should axial spondyloarthritis be diagnosed? *Nat Rev Rheumatol* 2017;13:264-5.
231. Braun J, Kay J. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. *Expert Opin Drug Saf* 2017;16:289-302.
232. Braun J, Baraliakos X, Hermann KG, Landewe R, Machado PM, Maksymowych WP, Davies O, Hoepken B, Nurminen T, Stach C, van der Heijde D. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. *RMD Open* 2017;3:10.

233. Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB, Grp MS. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. *Ann Rheum Dis* 2017;76:1070-7.
234. Braun J. Cardiovascular Comorbidities In Reply. *Dtsch Arztebl Int* 2017;114:560-.
235. Baraliakos X, Sieper J, Chen S, Pangan AL, Anderson JK. Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time. *Rheumatology* 2017;56:1162-6.
236. Baraliakos X, Kiltz U, Peters S, Appel H, Dybowski F, Igelmann M, Kalthoff L, Krause D, Menne HJ, Saracbası-Zender E, Schmitz-Bortz E, Vigneswaran M, Braun J. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. *Rheumatology* 2017;56:95-102.
237. Baraliakos X, Kiltz U, Appel H, Dybowski F, Igelmann M, Kalthoff L, Klink C, Krause D, Saracbası E, Schmitz-Bortz E, Rahmeh F, Braun J. Chronic but not inflammatory changes at the Achilles' tendon differentiate patients with peripheral spondyloarthritis from other diagnoses - Results from a prospective clinical trial. *RMD Open* 2017;3:10.
238. Baraliakos X, Fruth M, Kiltz U, Braun J. Inflammatory Spinal Diseases: axial Spondyloarthritis Central Importance of Imaging. *Z Rheumatol* 2017;76:149-62.
239. Baraliakos X, Fruth M, Braun J. Imaging of the sacroiliac joints. *Z Rheumatol* 2017;76:876-88.
240. Baraliakos X. Imaging in Axial Spondyloarthritis. *Isr Med Assoc J* 2017;19:712-8.
241. Bacchiega ABS, Balbi GGM, Ochtrop MLG, de Andrade FA, Levy RA, Baraliakos X. Ocular involvement in patients with spondyloarthritis. *Rheumatology* 2017;56:2060-7.
242. Andreasen RA, Kristensen LE, Ellingsen T, Christensen R, Baraliakos X, Wied J, Aalykke C, Ulstrup T, Schiottz-Christensen B, Horn HC, Emamifar A, Duerlund B, Fischer L, Hansen IMJ. Clinical characteristics of importance to outcome in patients with axial spondyloarthritis: protocol for a prospective descriptive and exploratory cohort study. *BMJ Open* 2017;7:10.
243. Talli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Canete JD, de Vlam K, de Wit M, Heiberg T, Helliwell P, Kalyoncu U, Kiltz U, Maccarone M, Niedermayer D, Otsa K, Scrivo R, Smolen JS, Stamm T, Veale DJ, Kvien TK, Gossec L. Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. *Joint Bone Spine* 2016;83:335-40.
244. Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, Syrbe U, Braun J, Rudwaleit M. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). *Ann Rheum Dis* 2016;75:1438-43.
245. Sepriano A, Landewe R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Ozgocmen S, Roussou E, Scarpato S, Sorensen IJ, Valle-Onate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M, Asas. Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. *Ann Rheum Dis* 2016;75:1034-42.
246. Riemekasten G, Aringer M, Baerwald C, Meyer-Bahlburg A, Bergner R, Feuchtenberger M, Gebhardt C, Hellmich B, Keysser G, Lorenz HM, Kneitz C, Witte T, Muller-Ladner U, Schneider M, Braun J, Rautenstrauch J, Specker C, Schulze-Koops H. Rheumatology - Integration into student training (RISA). Current structure of clinical rheumatology in German universities (RISA III). *Z Rheumatol* 2016;75:493-501.

247. Reusch A, Braun J, Ehlebracht-Konig I, Lind-Albrecht G, Janiche H, Lakomek HJ, Lakomek M, Rautenstrauch J, Kuffner R. Framework concept for education of patients with rheumatism. *Z Rheumatol* 2016;75:950-3.
248. Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort. *Ann Rheum Dis* 2016;75:2114-8.
249. Poddubnyy D, Fedorova A, Listing J, Haibel H, Baraliakos X, Braun J, Sieper J. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-alpha Inhibitors for Up to 10 Years. *J Rheumatol* 2016;43:2142-8.
250. Patermann J, Ehlebracht-Konig I, Lind-Albrecht G, Genth E, Reusch A, Kuffner R, Muller-Ladner U, Braun J. EULAR recommendations for patient education of people with inflammatory arthritis. Translation and evaluation in Germany. *Z Rheumatol* 2016;75:187-+.
251. Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJO, Kang SW, Anderson D, Blanco F, Hong SS, Lee SH, Braun J. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. *Arthritis Res Ther* 2016;18:11.
252. Molto A, Etcheto A, van der Heijde D, Landewe R, van den Bosch F, Molano WB, Burgos-Vargas R, Cheung PP, Collantes-Estevez E, Deodhar A, El-Zorkany B, Erdes S, Gu JR, Hajjaj-Hassouni N, Kiltz U, Kim TH, Kishimoto M, Luo SF, Machado PM, Maksymowych WP, Maldonado-Cocco J, Marzo-Ortega H, Montecucco CM, Ozgocmen S, van Gaalen F, Dougados M. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. *Ann Rheum Dis* 2016;75:1016-23.
253. Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Van den Bosch F, Logeart I, Wajdula J, Jones H, Marshall L, Bonin R, Pedersen R, Vlahos B, Kotak S, Bukowski JF. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. *Ann Rheum Dis* 2016;75:1328-35.
254. Machado PM, Baraliakos X, van der Heijde D, Braun J, Landewe R. MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. *Ann Rheum Dis* 2016;75:1486-93.
255. Lambert RGW, Bakker PAC, van der Heijde D, Weber U, Rudwaleit M, Hermann KGA, Sieper J, Baraliakos X, Bennett A, Braun J, Burgos-Vargas R, Dougados M, Pedersen SJ, Jurik AG, Maksymowych WP, Marzo-Ortega H, Ostergaard M, Poddubnyy D, Reijniere M, van den Bosch F, van der Horst-Bruinsma I, Landewe R. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. *Ann Rheum Dis* 2016;75:1958-63.
256. Krause D, Gabriel B, Herborn G, Braun J, Rau R. Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis. *Clin Rheumatol* 2016;35:1123-7.
257. Kiltz U, Winter J, Schirmer M, Weber U, Hammel L, Baraliakos X, Braun J. German translation and cross-cultural adaptation of the ASAS health index. An ICF-based instrument for documentation of functional ability in patients with ankylosing spondylitis. *Z Rheumatol* 2016;75:993-8.

258. Kiltz U, van der Heijde D, Boonen A, Bautista-Molano W, Burgos-Vargas R, Chiowchanwisawakit P, Duruoz T, El-Zorkany B, Essers I, Gaydukova I, Geher P, Gossec L, Grazio S, Gu J, Khan MA, Kim TJ, Maksymowych WP, Marzo-Ortega H, Navarro-Compan V, Olivieri I, Patrikos D, Pimentel-Santos FM, Schirmer M, van den Bosch F, Weber U, Zochling J, Braun J. Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. *RMD Open* 2016;2:5.
259. Kiltz U, Sieper J, Backhaus M, Buss B, Gromnica-Ihle E, Haibel H, Hammel L, Karberg K, Rehart S, Rudwaleit M, Schuch F, Steffens-Korbanka P, Braun J. "Treat-to-target (T2T)" Recommendation for the Treatment of the Patients with Spondyloarthritis Translation into German. *Z Rheumatol* 2016;75:903-9.
260. Kiltz U, Braun J. S2e-Guidelines "Gouty Arthritis - specialist". *Z Rheumatol* 2016;75:S9-S10.
261. Kiltz U, Boonen A, Braun J, Richter JG. Electronic assessment of disease activity and functioning in patients with axial spondyloarthritis: challenges and unmet needs. *Clin Exp Rheumatol* 2016;34:S57-S61.
262. Kiltz U, Baraliakos X, Braun J. Management of axial spondyloarthritis. *Internist* 2016;57:1060-8.
263. Kiltz U, Alten R, Fleck M, Kruger K, Manger B, Muller-Ladner U, Nusslein H, Reuss-Borst M, Schwarting A, Schulze-Koops H, Tausche A, Braun J. Full version of the S2e-Guidelines on Gouty Arthritis: Evidence-based Guidelines of the German Society of Rheumatology (DGRh). *Z Rheumatol* 2016;75:S11-S60.
264. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou YY, Goldstein N, Braun J. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. *J Rheumatol* 2016;43:2120-30.
265. Isaacs JD, Cutolo M, Keystone EC, Park W, Braun J. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. *J Intern Med* 2016;279:41-59.
266. Inman RD, Baraliakos X, Hermann KGA, Braun J, Deodhar A, van der Heijde D, Xu S, Hsu B. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. *Arthritis Res Ther* 2016;18:7.
267. Herregods N, Dehoorne J, Jaremko J, Joos R, Baraliakos X, Verstraete K, Jans L. Diagnostic Value of MRI of the Sacroiliac Joints in Juvenile Spondyloarthritis. *J Belg Soc Radiol* 2016;100:14.
268. Henkemeier U, Alten R, Bannert B, Baraliakos X, Behrens F, Heldmann F, Kiltz U, Kohm M, Konig R, Leipe J, Muller-Ladner U, Rech J, Riechers E, Rubbert-Roth A, Schmidt RE, Schulze-Koops H, Specker C, Tausche AK, Wassenberg S, Witt M, Witte T, Zernicke J, Burkhardt H. Do we still need clinical studies in rheumatology? *Z Rheumatol* 2016;75:4-10.
269. Heldmann F, Baraliakos X, Kiltz U, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Gaston H, Gruenke M, Witt M, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Braun J. Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety. *Clin Exp Rheumatol* 2016;34:184-90.
270. Hammoudeh M, Abdulaziz S, Alosaimi H, Al-Rayes H, Sarakbi HA, Baamer M, Baraliakos X, Makhoulfi CD, Janoudi N, Shirazy K, Sieper J, Sukhbir U. Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus. *J Int Med Res* 2016;44:216-30.

271. Gudu T, Etcheto A, de Wit M, Heiberg T, Maccarone M, Balanescu A, Balint PV, Niedermayer DS, Canete JD, Helliwell P, Kalyoncu U, Kiltz U, Otsal K, Veale DJ, de Vlam K, Scivo R, Stamm T, Kvien TK, Gossec L. Fatigue in psoriatic arthritis - a cross-sectional study of 246 patients from 13 countries. *Joint Bone Spine* 2016;83:439-43.
272. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewe R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Canete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis* 2016;75:499-510.
273. Deodhar A, Strand V, Kay J, Braun J. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. *Ann Rheum Dis* 2016;75:791-4.
274. Braun J, Schneider M, Lakomek HJ. Cornerstones of quality assurance in medicine in Germany. Important impulse for the situation in treatment of rheumatism. *Z Rheumatol* 2016;75:203-12.
275. Braun J, Robbers J, Lakomek HJ. Quality of German medical services: a review. *Z Rheumatol* 2016;75:97-102.
276. Braun J, Kudrin A. Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health. *Biologicals* 2016;44:257-66.
277. Braun J, Krause A, Aringer M, Burmester G, Bessler F, Engel JM, Faubel U, Fischer-Betz R, Genth E, Gromnica-Ihle E, Hellmich B, Kotter I, Kruger K, Lakomek J, Lorenz HM, Manger B, Marker-Hermann E, Minden K, Muller-Ladner U, Rautenstrauch J, Rehart S, Riemekasten G, Rudwaleit M, Ruther W, Schett G, Schuch F, Schulze-Koops H, Specker C, Wassenberg S, Wiek D, Zink A, Schneider M. Standards of care for people with rheumatoid arthritis in Europe. Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsche Rheumaliga". *Z Rheumatol* 2016;75:416-28.
278. Braun J, Bessler F, Lakomek HJ, Rudwaleit M. International quality indicators in rheumatology. Suggestions for rheumatoid arthritis. *Z Rheumatol* 2016;75:330-7.
279. Braun J, Baraliakos X, Kiltz U. Non-radiographic axial spondyloarthritis: a classification or a diagnosis? *Clin Exp Rheumatol* 2016;34:S5-S6.
280. Braun J, Baraliakos X, Kiltz U. Secukinumab (AIN457) in the treatment of ankylosing spondylitis. *Expert Opin Biol Ther* 2016;16:711-22.
281. Braun J, Baraliakos X, Hermann KGA, Xu S, Hsu B. Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab. *J Rheumatol* 2016;43:901-6.
282. Braun J, Baraliakos X, Hermann KGA, Xu S, Hsu B. Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab. *J Rheumatol* 2016;43:1704-12.
283. Braun J, Baraliakos X. Magnetic Resonance Imaging in Rheumatology. *Z Rheumatol* 2016;75:582-5.
284. Braun J. Response to: "Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRA main and extension studies: utility of laboratory methods description' by Francesca Meacci et al. *Ann Rheum Dis* 2016;75:E63-U4.
285. Braun J. New targets in psoriatic arthritis. *Rheumatology* 2016;55:30-7.

286. Baraliakos X, Maksymowych WP. Imaging in the diagnosis and management of axial spondyloarthritis. *Best Pract Res Clin Rheumatol* 2016;30:608-23.
287. Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE, Krause A, Schmidt R, Schneider M, Sieper J, Andermann B, van Tubergen A, Witt M, Braun J. Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. *RMD Open* 2016;2:3.
288. Baraliakos X, Heldmann F, Callhoff J, Suppiah R, McQueen FM, Krause D, Klink C, Schmitz-Bortz E, Igelmann M, Kalthoff L, Kiltz U, Schmuedderich A, Braun J. Quantification of Bone Marrow Edema by Magnetic Resonance Imaging Only Marginally Reflects Clinical Neck Pain Evaluation in Rheumatoid Arthritis and Ankylosing Spondylitis. *J Rheumatol* 2016;43:2131-5.
289. Baraliakos X, Braun J. Imaging Scoring Methods in Axial Spondyloarthritis. *Rheum Dis Clin North Am* 2016;42:663-+.
290. Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, Emery P, McInnes IB, van Laar JM, Wordsworth P, Wollenhaupt J, Kellner H, Colin L, Vandenhende F, Radford K, Hueber W. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. *Ann Rheum Dis* 2016;75:408-12.
291. Tran-Duy A, Nguyen TTV, Thijs H, Baraliakos X, Heldmann F, Braun J, Boonen A. Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis. *Arthritis Care Res* 2015;67:1578-85.
292. Sieper J, Landewe R, Rudwaleit M, van der Heijde D, Dougados M, Mease PJ, Braun J, Deodhar A, Kivitz A, Walsh J, Hoepken B, Nurminen T, Maksymowych WP. Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis. *Arthritis Rheumatol* 2015;67:668-77.
293. Sieper J, Braun J, Kay J, Badalamenti S, Radin AR, Jiao LX, Fiore S, Momtahn T, Yancopoulos GD, Stahl N, Inman RD. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). *Ann Rheum Dis* 2015;74:1051-7.
294. Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. *Nat Rev Dis Primers* 2015;1:16.
295. Sieper J, Braun J. Lessons learnt from 15 years of investigator-initiated trials on axial spondyloarthritis. *Z Rheumatol* 2015;74:125-31.
296. Poddubnyy D, Haibel H, Braun J, Rudwaleit M, Sieper J. Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort. *Arthritis Rheumatol* 2015;67:2369-75.
297. Mandl P, Navarro-Compan V, Terslev L, Aegerter P, van der Heijde D, D'Agostino MA, Baraliakos X, Pedersen SJ, Jurik AG, Naredo E, Schueller-Weidekamm C, Weber U, Wick MC, Bakker PAC, Filippucci E, Conaghan PG, Rudwaleit M, Schett G, Sieper J, Tarp S, Marzo-Ortega H, Ostergaard M. EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. *Ann Rheum Dis* 2015;74:1327-39.
298. Krause D, Gabriel B, Herborn G, Braun J, Rau R. Radiologic damage at baseline predicts patient-related outcomes 18 years after the initiation of methotrexate therapy in patients with severe rheumatoid arthritis. *Clin Exp Rheumatol* 2015;33:611-6.

299. Kisters K, Baraliakos X, Tokmak F, Gremmler B, Grober U. Magnesium and vitamin D are synergistic - vitamin D resistance in magnesium deficiency in hypertension and diabetes mellitus. *Trace Elem Electrolytes* 2015;32:42-.
300. Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G, Khan MA, Maksymowych WP, Marzo-Ortega H, Reveille J, Stebbings S, Bostan C, Braun J. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. *Ann Rheum Dis* 2015;74:830-5.
301. Kiltz U. Use of TNF inhibition therapy in patients with axial spondyloarthritis. *Z Rheumatol* 2015;74:263-4.
302. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. *Ann Rheum Dis* 2015;74:538-46.
303. Herregods N, Jaremko JL, Baraliakos X, Dehoorne J, Leus A, Verstraete K, Jans L. Limited role of gadolinium to detect active sacroiliitis on MRI in juvenile spondyloarthritis. *Skeletal Radiol* 2015;44:1637-46.
304. Herregods N, Dehoorne J, Pattyn E, Jaremko JL, Baraliakos X, Elewaut D, Van Vlaenderen J, Van den Bosch F, Joos R, Verstraete K, Jans L. Diagnostic value of pelvic enthesitis on MRI of the sacroiliac joints in enthesitis related arthritis. *Pediatr Rheumatol* 2015;13:9.
305. Herregods N, Dehoorne J, Joos R, Jaremko JL, Baraliakos X, Leus A, Van den Bosch F, Verstraete K, Jans L. Diagnostic value of MRI features of sacroiliitis in juvenile spondyloarthritis. *Clin Radiol* 2015;70:1428-38.
306. Essers I, van Tubergen A, Heldmann F, Baraliakos X, Braun J, Kiltz U, Boonen A. Do patients with ankylosing spondylitis adapt to their disease? Evidence from a 'then-test' in patients treated with TNF inhibitors. *RMD Open* 2015;1:8.
307. Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou YY, Xu S, Han CL, Hsu B. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. *Ann Rheum Dis* 2015;74:757-61.
308. Buchbender C, Ostendorf B, Ruhlmann V, Heusch P, Miese F, Beiderwellen K, Schneider M, Braun J, Antoch G, Baraliakos X. Hybrid 18F-labeled Fluoride Positron Emission Tomography/Magnetic Resonance (MR) Imaging of the Sacroiliac Joints and the Spine in Patients with Axial Spondyloarthritis: A Pilot Study Exploring the Link of MR Bone Pathologies and Increased Osteoblastic Activity. *J Rheumatol* 2015;42:1631-7.
309. Braun J, Kudrin A. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. *Immunotherapy* 2015;7:73-87.
310. Braun J, Kiltz U, Sarholz M, Heldmann F, Regel A, Baraliakos X. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. *Expert Rev Clin Immunol* 2015;11:935-46.
311. Braun J, Kiltz U, Heldmann F, Baraliakos X. Emerging drugs for the treatment of axial and peripheral spondyloarthritis. *Expert Opin Emerg Drugs* 2015;20:1-14.
312. Braun J, Baraliakos X, Kiltz U, Heldmann F, Sieper J. Classification and Diagnosis of Axial Spondyloarthritis - What Is the Clinically Relevant Difference? *J Rheumatol* 2015;42:31-8.
313. Braun J. Current Therapy of axial Spondyloarthritis. *Drug Res* 2015;65:S8-S10.
314. Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials. *J Rheumatol* 2015;42:1418-26.

315. Baraliakos X, Coates LC, Braun J. The involvement of the spine in psoriatic arthritis. *Clin Exp Rheumatol* 2015;33:S31-S5.
316. Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? *RMD Open* 2015;1:4.
317. Baraliakos X. The contribution of imaging in the diagnosis and treatment of axial spondyloarthritis. *Eur J Clin Invest* 2015;45:81-6.
318. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofo S, Richards HB, Measure, Grp MS. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. *N Engl J Med* 2015;373:2534-48.
319. van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han CL, Investigators G-R. The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial. *J Rheumatol* 2014;41:1095-103.
320. Trampisch US, Krause D, Trampisch HJ, Klaassen-Mielke R, Baraliakos X, Braun J. Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. *Trials* 2014;15:7.
321. Smolen JS, Braun J, Dougados M, Emery P, FitzGerald O, Helliwell P, Kavanaugh A, Kvien TK, Landewe R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, de Wit M, Baraliakos X, Betteridge N, Burgos-Vargas R, Collantes-Estevez E, Deodhar A, Elewaut D, Gossec L, Jongkees M, Maccarone M, Redlich K, van den Bosch F, Wei JCC, Winthrop K, van der Heijde D. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. *Ann Rheum Dis* 2014;73:6-16.
322. Schoels MM, Braun J, Dougados M, Emery P, Fitzgerald O, Kavanaugh A, Kvien TK, Landewe R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Sieper J, Smolen JS, de Wit M, van der Heijde D. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. *Ann Rheum Dis* 2014;73:238-42.
323. Poddubnyy D, Conrad K, Haibel H, Syrbe U, Appel H, Braun J, Rudwaleit M, Sieper J. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. *Ann Rheum Dis* 2014;73:2137-43.
324. Meyer MF, Braun J. Relevance of the current discussion on prioritization for rheumatology. *Z Rheumatol* 2014;73:758-64.
325. McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, Dahmen G, Wollenhaupt J, Schulze-Koops H, Kogan J, Ma SL, Schumacher MM, Bertolino AP, Hueber W, Tak PP. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. *Ann Rheum Dis* 2014;73:349-56.
326. Marker-Hermann E, Kiltz U, Braun J. Treatment of chronic back pain. Current standards. *Internist* 2014;55:1410-8.
327. Lorenz HM, Braun J, Kruger K, Schneider M. Introduction and Use of "biosimilars" in the Treatment of inflammatory-rheumatic Diseases. *Z Rheumatol* 2014;73:784-6.
328. Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, Reveille JD, Rudwaleit M, van der Heijde D, Stach C, Hoepken B, Fichtner A, Coteur G, de Longueville M, Sieper J. Efficacy of certolizumab



pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. *Ann Rheum Dis* 2014;73:39-47.

329. Krause D, Gabriel B, Herborn G, Braun J, Rau R. The positive influence of methotrexate on the mortality of patients with rheumatoid arthritis is partly independent of its effect on disease activity: results of a re-evaluation 18 years after baseline. *Clin Exp Rheumatol* 2014;32:395-400.
330. Kiltz U, van der Heijde D, Boonen A, Braun J. The ASAS Health Index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis. *Clin Exp Rheumatol* 2014;32:S105-S8.
331. Kiltz U, Stemmer M, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:109-11.
332. Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Bohle E, Bohm H, Bohncke WH, Chenot JF, Heiligenhaus A, Jaresch S, Mau W, Oberschelp U, Pleyer U, Repschlager U, Schneider E, Smolenski U, Stallmach A, Stemmer M, Swoboda B, Ulrich C, Winking M, Braun J. DGRh-S3-Guideline Axial Spondyloarthritis including Morbus Bechterew and Early Forms. *Z Rheumatol* 2014;73:69-70.
333. Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Bohle E, Bohm H, Bohncke WH, Chenot JF, Heiligenhaus A, Hermann KG, Jaresch S, Mau W, Oberschelp U, Pleyer U, Repschlager U, Schneider E, Smolenski U, Stallmach A, Stemmer M, Swoboda B, Ulrich C, Winking M, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:26-7.
334. Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Bohle E, Bohm H, Bohncke WH, Chenot JF, Heiligenhaus A, Hermann KG, Jaresch S, Mau W, Oberschelp U, Pleyer U, Repschlager U, Schneider E, Smolenski U, Stallmach A, Stemmer M, Swoboda B, Ulrich C, Winking M, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:23-5.
335. Kiltz U, Sieper J, Kellner H, Krause D, Rudwaleit M, Chenot JF, Stallmach A, Jaresch S, Braun J. DGRh-S3-Guideline Axial Spondyloarthritis including Ankylosing Spondylitis and Early Forms. *Z Rheumatol* 2014;73:78-+.
336. Kiltz U, Rudwaleit M, Sieper J, Krause D, Oberschelp U, Schneider E, Swoboda B, Bohm H, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:66-8.
337. Kiltz U, Rudwaleit M, Sieper J, Krause D, Hermann KG, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:49-+.
338. Kiltz U, Rudwaleit M, Sieper J, Krause D, Heiligenhaus A, Pleyer U, Chenot JF, Stallmach A, Jaresch S, Oberschelp U, Schneider E, Swoboda B, Bohm H, Hermann KG, Bohncke WH, Braun J. German Society for Rheumatology-S3-Guidelines on Axial Spondyloarthritis including Morbus Bechterew and Early Forms. *Z Rheumatol* 2014;73:44-8.
339. Kiltz U, Rudwaleit M, Sieper J, Krause D, Chenot JF, Stallmach A, Jaresch S, Oberschelp U, Schneider E, Swoboda B, Bohm H, Heiligenhaus A, Pleyer U, Bohncke WH, Stemmer M, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:28-+.
340. Kiltz U, Rudwaleit M, Sieper J, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:40-+.
341. Kiltz U, Oberschelp U, Schneider E, Swoboda B, Bohm H, Winking M, Ulrich C, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:97-100.

342. Kiltz U, Mau W, Smolenski U, Repschlagel U, Bohle E, Stemmer M, Oberschelp U, Schneider E, Swoboda B, Bohm H, Braun J. DGRh-S3-Guidelines on Axial Spondyloarthritis including Morbus Bechterew and Early Forms. *Z Rheumatol* 2014;73:71-7.
343. Kiltz U, Mau W, Repschlagel U, Bohle E, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:104-8.
344. Kiltz U, Mau W, Repschlagel U, Bohle E, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:101-3.
345. Kiltz U, Braun J. German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms. *Z Rheumatol* 2014;73:20-2.
346. Heldmann F, Kiltz U, Baraliakos X, Braun J. SAPHO syndrome. *Z Rheumatol* 2014;73:729-41.
347. Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. *Ann Rheum Dis* 2014;73:243-6.
348. Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scivo R, MacCarone M, Carton L, Otsa K, Sooaar I, Heiberg T, Bertheussen H, Canete JD, Lombarte AS, Balanescu A, Dinte A, de Vlam K, Smolen JS, Stamm T, Niedermayer D, Bekes G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK, Taskforce EP. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. *Ann Rheum Dis* 2014;73:1012-9.
349. Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, Miceli-Richard C, Wei JCC, Pedersen R, Bonin R, Rahman MU, Logeart I, Wajdula J, Koenig AS, Vlahos B, Alvarez D, Bukowski JF. Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis Rheumatol* 2014;66:2091-102.
350. Deodhar A, Reveille JD, van den Bosch F, Braun J, Burgos-Vargas R, Caplan L, Clegg DO, Colbert RA, Gensler LS, van der Heijde D, van der Horst-Bruinsma IE, Inman RD, Maksymowych WP, Mease PJ, Raychaudhuri S, Reimold A, Rudwaleit M, Sieper J, Weisman MH, Landewe RBM. The Concept of Axial Spondyloarthritis. *Arthritis Rheumatol* 2014;66:2649-56.
351. Braun J, Kiltz U, Baraliakos X, van der Heijde D. Optimisation of rheumatology assessments - the actual situation in axial spondyloarthritis including ankylosing spondylitis. *Clin Exp Rheumatol* 2014;32:S96-S104.
352. Braun J, Baraliakos X, Regel A, Kiltz U. Assessment of spinal pain. *Best Pract Res Clin Rheumatol* 2014;28:875-87.
353. Braun J, Baraliakos X, Hermann KGA, Deodhar A, van der Heijde D, Inman R, Beutler A, Zhou YY, Xu S, Hsu B. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. *Ann Rheum Dis* 2014;73:1107-13.
354. Braun J, Baraliakos X, Heldmann F, Kiltz U. What is ascertained in the Therapy of axial Spondyloarthritis? (vol 55, pg 106, 2014). *Internist* 2014;55:106-.
355. Braun J, Baraliakos X, Heldmann F, Kiltz U. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. *Expert Opin Investig Drugs* 2014;23:647-59.
356. Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester GR, Dougados M, Emery P, Gaston H, Grunke M, Van Der Horst-Bruinsma IE, Landewe R, Leirisalo-

- Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. *Ann Rheum Dis* 2014;73:1819-25.
357. Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. *Ann Rheum Dis* 2014;73:710-5.
358. Baraliakos X, Deodhar A. Unanswered questions in the management of axial spondyloarthritis: an opinion piece. *Clin Rheumatol* 2014;33:1359-65.
359. Baraliakos X, Baerlecken N, Witte T, Heldmann F, Braun J. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. *Ann Rheum Dis* 2014;73:1079-82.
360. Baeten D, Baraliakos X, Braun J. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial (vol 382, pg 1705, 2013). *Lancet* 2014;383:1548-.
361. Albrecht K, Kruger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester G, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nusslein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Muller-Ladner U. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. *Rheumatol Int* 2014;34:1-9.
362. van der Heijde D, Braun J, Deodhar A, Inman RD, Xu S, Mack ME, Hsu B. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). *Rheumatology* 2013;52:321-5.
363. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Haug-Rost I, Braun J, Sieper J. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. *Ann Rheum Dis* 2013;72:305-6.
364. Song IH, Haibel H, Poddubnyy D, Braun J, Sieper J. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. *Clin Exp Rheumatol* 2013;31:S37-S42.
365. Pollet S, Pollet SE, Maudanz MJ, Baraliakos X, Kisters K. Blockade of the NMDA (N-methyl-d-aspartic acid) receptor, regulation of the calcium flux Possible mechanisms for neuroprotective effects of magnesium. *Trace Elem Electrolytes* 2013;30:59-65.
366. Poddubnyy D, Gaydukova I, Hermann KG, Song IH, Haibel H, Braun J, Sieper J. Magnetic Resonance Imaging Compared to Conventional Radiographs for Detection of Chronic Structural Changes in Sacroiliac Joints in Axial Spondyloarthritis. *J Rheumatol* 2013;40:1557-65.
367. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Urena S, Lim M, Lee YA, Lee SJ, Kim H, Yoo DH, Braun J. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. *Ann Rheum Dis* 2013;72:1605-12.
368. Machado P, Landewe R, Braun J, Baraliakos X, Hermann KGA, Hsu B, Baker D, van der Heijde D. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. *Ann Rheum Dis* 2013;72:1104-7.

369. Kiltz U, Sieper J, Braun J. ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis. Evaluation of the 2010 update in the German-speaking area. *Z Rheumatol* 2013;72:81-8.
370. Kiltz U, Sieper J, Braun J. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Evaluation of the 2010 update in the German-speaking area. *Z Rheumatol* 2013;72:71-80.
371. Kiltz U, Baraliakos X, Braun J, van der Heijde D. Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design? *Clin Exp Rheumatol* 2013;31:S47-S50.
372. Kiltz U, Baraliakos X, Braun J. The Concept of Non-Radiographic Axial Spondyloarthritis. *Aktuelle Rheumatol* 2013;38:92-6.
373. Hausler U, Guminski B, Helmchen U, Kisters K, Heinz C, Braun J. Tubulointerstitial nephritis with uveitis (TINU) syndrome. A relatively rare rheumatological differential diagnosis with unexplained uveitis. *Z Rheumatol* 2013;72:393-7.
374. Haibel H, Heldmann F, Braun J, Listing J, Kupper H, Sieper J. Long-Term Efficacy of Adalimumab After Drug Withdrawal and Retreatment in Patients With Active Non-Radiographically Evident Axial Spondyloarthritis Who Experience a Flare. *Arthritis Rheum* 2013;65:2211-3.
375. Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dorner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel P, Weisman MH, Winthrop KL. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Ann Rheum Dis* 2013;72:2-34.
376. Carmona L, Sellas A, Rodriguez-Lozano C, Juanola X, Llorente JFG, Sueiro JLF, Linares LF, de Castro MC, Moreno M, Zarco P, Ariza R, Baraliakos X, de Miguel E. Scoring with the Berlin MRI method for assessment of spinal inflammatory activity in patients with ankylosing spondylitis: a calibration exercise among rheumatologists. *Clin Exp Rheumatol* 2013;31:883-8.
377. Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. *Clin Exp Rheumatol* 2013;31:S33-S6.
378. Braun J, Baraliakos X, Hermann KGA. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study (vol 71, pg 878, 2012). *Ann Rheum Dis* 2013;72:788-.
379. Braun J. What is ascertained in the therapy of axial spondyloarthritis? *Internist* 2013;54:1450-7.
380. Braun A, Gnann H, Saracbası E, Grifka J, Kiltz U, Letschert K, Braun J. Optimizing the identification of patients with axial spondyloarthritis in primary care-the case for a two-step strategy combining the most relevant clinical items with HLA B27. *Rheumatology* 2013;52:1418-24.
381. Baraliakos X, Listing J, Haibel H, Sieper J, Braun J. Vertebral Erosions Associated with Spinal Inflammation in Patients with Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes After 2 Years of Tumor Necrosis Factor Inhibitor Therapy. *J Rheumatol* 2013;40:1891-6.
382. Baraliakos X, Kiltz U, Heldmann F, Sieper J, Braun J. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. *Clin Exp Rheumatol* 2013;31:S43-S6.
383. Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. *Arthritis Res Ther* 2013;15:9.

384. Baraliakos X, Braun J. OPINION Perspectives on imaging in axial spondyloarthritis. *Nat Rev Rheumatol* 2013;9:498-502.
385. Baraliakos X, Braun J. Response to 'Evidence in Support of the Validity of the TNF Brake Hypothesis' by Maksymowych. *Ann Rheum Dis* 2013;72:E32-E3.
386. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei JW, Brachat A, Bek S, Laurent D, Li YL, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet* 2013;382:1705-13.
387. Wagner C, Visvanathan S, Braun J, van der Heijde D, Deodhar A, Hsu B, Mack M, Elashoff M, Inman RD. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. *Ann Rheum Dis* 2012;71:674-80.
388. van Werde M, Ruetten S, Baraliakos X, Godolias G, Braun J. Differential diagnosis of back pain in patients with ankylosing spondylitis: instable cervical spine fracture. *Dtsch Med Wochenschr* 2012;137:1740-2.
389. van der Heijde D, Machado P, Braun J, Hermann KGA, Baraliakos X, Hsu B, Baker D, Landewe R. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. *Ann Rheum Dis* 2012;71:369-73.
390. van der Heijde D, Deodhar A, Inman RD, Braun J, Hsu B, Mack M. Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study. *Arthritis Care Res* 2012;64:1919-22.
391. van den Berg R, Baraliakos X, Braun J, van der Heijde D. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. *Rheumatology* 2012;51:1388-96.
392. Sieper J, Braun J. How Important is Early Therapy in Axial Spondyloarthritis? *Rheum Dis Clin North Am* 2012;38:635-+.
393. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. *Ann Rheum Dis* 2012;71:1616-22.
394. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. *Arthritis Rheum* 2012;64:1388-98.
395. Machado P, Landewe RBM, Braun J, Baraliakos X, Hermann KGA, Hsu B, Baker D, van der Heijde D. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. *Ann Rheum Dis* 2012;71:2002-5.
396. Kruger K, Wollenhaupt J, Albrecht K, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester G, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nusslein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Muller-Ladner U. German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm. *Z Rheumatol* 2012;71:592-+.

397. Kisters K, Wessels F, Nguyen MQ, Mitchell A, Gremmler B, Funke C, Baraliakos X, Kask B, Hausberg M, Hunger R, Liebscher DH, Liebscher U, Tokmak F. Magnesium therapy in borderline hypertension. *Trace Elem Electrolytes* 2012;29:113-6.
398. Kiltz U, Heldmann F, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? *Curr Opin Rheumatol* 2012;24:252-60.
399. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, Krause D, Schmitz-Bortz E, Florecke M, Bollow M, Braun J. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. *Ann Rheum Dis* 2012;71:1207-11.
400. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, Krause D, Schmitz-Bortz E, Florecke M, Bollow M, Braun J. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? *Arthritis Care Res* 2012;64:1415-22.
401. Kiltz U, Baraliakos X, Braun J. Spondyloarthritis - the novel concept. An introduction to the diagnosis and treatment of axial spondyloarthritis. *Dtsch Med Wochenschr* 2012;137:1745-7.
402. Hermann KGA, Baraliakos X, van der Heijde D, Jurik AG, Landewe R, Marzo-Ortega H, Ostergaard M, Rudwaleit M, Sieper J, Braun J, Assessment SpondyloArthritis I. Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. *Ann Rheum Dis* 2012;71:1278-88.
403. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, Baraliakos X, Listing J, Rudwaleit M, Schett G, Sieper J. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. *Ann Rheum Dis* 2012;71:572-4.
404. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Canete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewe R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. *Ann Rheum Dis* 2012;71:4-12.
405. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dorner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel P, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. *Ann Rheum Dis* 2012;71:2-45.
406. Fendler C, Saracbası E, Dybowski F, Heldmann F, Braun J. Practical problems by implementation of vaccination recommendations. *Z Rheumatol* 2012;71:147-+.
407. Dougados M, Braun J, Vargas RB, Gossec L, Maksymowych W, Sieper J, van der Heijde D. ASAS recommendations for variables to be collected in clinical trials/epidemiological studies of spondyloarthritis. *Ann Rheum Dis* 2012;71:1103-4.
408. Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, Logeart I. Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: Example of etanercept in advanced ankylosing spondylitis. *Arthritis Care Res* 2012;64:290-4.

409. Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, Logeart I. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. *Rheumatology* 2012;51:1687-96.
410. Burgos-Vargas R, Braun J. Inflammatory Back Pain. *Rheum Dis Clin North Am* 2012;38:487-+.
411. Braun J, Smolen JS. Gout: thoughts about a treat-to-target programme. *Clin Exp Rheumatol* 2012;30:S142-S4.
412. Braun J, Sieper J, Zink A. The risks of smoking in patients with spondyloarthritides. *Ann Rheum Dis* 2012;71:791-2.
413. Braun J, Sieper J, Zink A. The risks of smoking in patients with spondyloarthritides (Reprinted from *Ann Rheum Dis*, vol 71, pg 791-2, 2012). *Postgrad Med J* 2012;88:617-8.
414. Braun J, Sieper J. Classification, Diagnosis, and Referral of Patients with Axial Spondyloarthritis. *Rheum Dis Clin North Am* 2012;38:477-+.
415. Braun J, Sieper J. Spondyloarthritis Preface. *Rheum Dis Clin North Am* 2012;38:XVII-XXI.
416. Braun J, Schneider M, Genth E. Quo vadis Rheumatology Closed meetings of the Executive Board and the Advisory Board of DGRh 2011. *Z Rheumatol* 2012;71:456-8.
417. Braun J, Schneider M, Genth E. Rheumatology - current and future supply of flammable and non-flammable musculoskeletal diseases in Germany An Assessment of the Board of DGRh. *Z Rheumatol* 2012;71:544-+.
418. Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu SP, Hsu B. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. *Ann Rheum Dis* 2012;71:661-7.
419. Braun J, Baraliakos X, Hermann KGA, van der Heijde D, Inman RD, Deodhar AA, Baratlle A, Xu S, Xu WC, Hsu B. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo-controlled GO-RAISE study. *Ann Rheum Dis* 2012;71:878-84.
420. Braun J, Baraliakos X. SPONDYLOARTHROPATHIES The disease process in axial SpA: what can biomarkers tell us? *Nat Rev Rheumatol* 2012;8:8-10.
421. Braun J. Axial spondyloarthritis: thoughts about nomenclature and treatment targets. *Clin Exp Rheumatol* 2012;30:S132-S5.
422. Braun J. Rheumatology: present and future. *Dtsch Med Wochenschr* 2012;137:1735-.
423. Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. *Rheumatology* 2012;51:1378-87.
424. Baraliakos X, Listing J, Buschmann J, von der Recke A, Braun J. A Comparison of New Bone Formation in Patients With Ankylosing Spondylitis and Patients With Diffuse Idiopathic Skeletal Hyperostosis A Retrospective Cohort Study Over Six Years. *Arthritis Rheum* 2012;64:1127-33.
425. Baraliakos X, Hermann KGA, Braun J. Imaging in Axial Spondyloarthritis Diagnostic Problems and Pitfalls. *Rheum Dis Clin North Am* 2012;38:513-+.
426. Baraliakos X, Braun J. MRI examinations for axial and peripheral spondyloarthritis. *Z Rheumatol* 2012;71:27-37.

427. Baraliakos X, Braun J. Biologic Therapies for Spondyloarthritis: What Is New? *Curr Rheumatol Rep* 2012;14:422-7.
428. Vastesaeger N, van der Heijde D, Inman RD, Wang YX, Deodhar A, Hsu B, Rahman MU, Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. Predicting the outcome of ankylosing spondylitis therapy. *Ann Rheum Dis* 2011;70:973-81.
429. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, Rudwaleit M, Braun J, Assessment SpondyloArthritis Int S. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. *Ann Rheum Dis* 2011;70:905-8.
430. Swoboda B, Villiger P, Braun J. Elective rheumatology surgery from the perspective of the rheumatoid orthopaedist and the rheumatologist. *Z Rheumatol* 2011;70:7-8.
431. Song IH, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, Sieper J. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. *Ann Rheum Dis* 2011;70:1108-10.
432. Poddubnyy DA, Marker-Hermann E, Kaluza-Schilling W, Zeidler H, Braun J, Listing J, Sieper J, Rudwaleit M. Relation of HLA-B27, Tumor Necrosis Factor-alpha Promoter Gene Polymorphisms, and T Cell Cytokine Production in Ankylosing Spondylitis - A Comprehensive Genotype-Phenotype Analysis from an Observational Cohort. *J Rheumatol* 2011;38:2436-41.
433. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. *Ann Rheum Dis* 2011;70:1369-74.
434. Pincus T, Bijlsma JWW, Braun J, Buttgereit F, Cutolo M. Low-dose glucocorticoids in rheumatic diseases: Introduction. *Clin Exp Rheumatol* 2011;29:S2-S4.
435. Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D, Assessment SpondyloArthritis Int S. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. *Ann Rheum Dis* 2011;70:47-53.
436. Machado P, Landewe R, Braun J, Hermann KGA, Baraliakos X, Baker D, Hsu B, van der Heijde D. A stratified model for health outcomes in ankylosing spondylitis. *Ann Rheum Dis* 2011;70:1758-64.
437. Lakomek HJ, Robbers J, Koshedub R, Krause A, Braun J. How to finance and increase the appeal of rheumatology training. View of the Association of Rheumatology Clinics in Germany (VRA) on challenges and successful strategies. *Z Rheumatol* 2011;70:712-+.
438. Lakomek HJ, Braun J, Gromnica-Ihle E, Fiehn C, Claus S, Specker C, Jung J, Krause A, Lorenz HM, Robbers J. Amendment of the structural quality for inpatient rheumatology. *Z Rheumatol* 2011;70:615-9.
439. Krause D, Rau R, Braun J. Glucocorticoid treatment in early rheumatoid arthritis. *Clin Exp Rheumatol* 2011;29:S121-S5.
440. Kiltz U, van der Heijde D, Cieza A, Boonen A, Stucki G, Ustun B, Braun J. Developing and validating an index for measuring health in patients with ankylosing spondylitis. *Rheumatology* 2011;50:894-8.
441. Kiltz U, Sieper J, Braun J. Development of morbidity and mortality in patients with spondyloarthritis. *Z Rheumatol* 2011;70:473-+.
442. Kiltz U, Braun J. Gender Aspects in Patients with Spondyloarthritis. *Aktuelle Rheumatol* 2011;36:361-5.
443. Heldmann F, Dybowski F, Baraliakos X, Braun J. Perioperative use of biologicals in rheumatoid arthritis. *Z Rheumatol* 2011;70:14-20.



444. Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Geusens P, Gaston H, Schewe S, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Listing J, Braun J. The European Ankylosing Spondylitis Infiximab Cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab. *Clin Exp Rheumatol* 2011;29:672-80.
445. Heberlein I, Demary W, Bloching H, Braun J, Buttgereit F, Dreher R, Kuhn C, Lange U, Zink A, Zeidler H, Hantzel H, Raspe H. Diagnosis and treatment of osteoporosis and rheumatoid arthritis in accordance with German guidelines. *Z Rheumatol* 2011;70:592-+.
446. Heberlein I, Demary W, Bloching H, Braun J, Buttgereit F, Dreher R, Kuhn C, Lange U, Pollahne W, Zink A, Zeidler H, Hantzel H, Raspe H. Prophylaxis and treatment of osteoporosis in patients with rheumatoid arthritis (ORA study). *Z Rheumatol* 2011;70:793-+.
447. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dorner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel P, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. *Ann Rheum Dis* 2011;70:I2-I36.
448. Fendler C, Baraliakos X, Braun J. Glucocorticoid treatment in spondyloarthritis. *Clin Exp Rheumatol* 2011;29:S139-S42.
449. Dybowski F, Moos F, Saracbas-Zender E, Heldmann F, Braun J. Generalized osteoarthritis in a young adult with type II collagenopathy. *Dtsch Med Wochenschr* 2011;136:2147-51.
450. Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, van der Heijde D. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. *Ann Rheum Dis* 2011;70:249-51.
451. Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, Thabut G, Leblanc V, Logeart I. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). *Ann Rheum Dis* 2011;70:799-804.
452. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). *Ann Rheum Dis* 2011;70:755-9.
453. Braun J, Wollenhaupt J, Genth E. Further education: a core responsibility of the German Society for Rheumatology and the Rheuma Academy. *Z Rheumatol* 2011;70:701-+.
454. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien TK, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen BJ, van der Heijde D. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2011;70:896-904.
455. Braun J, Rudwaleit M, Sieper J. Spondyloarthritis. *Internist* 2011;52:657-+.
456. Braun J, Baraliakos X. Imaging of axial spondyloarthritis including ankylosing spondylitis. *Ann Rheum Dis* 2011;70:I97-I103.
457. Braun J. Arthritis of the atlanto-axial joint with inflammatory neck pain as a primary manifestation of seronegative rheumatoid arthritis. *Dtsch Med Wochenschr* 2011;136:331-2.

458. Braun A, Saracbası E, Grifka J, Schnitker J, Braun J. Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain? *Ann Rheum Dis* 2011;70:1782-7.
459. Baraliakos X, van der Heijde D, Braun J, Landewe RBM. OMERACT Magnetic Resonance Imaging Initiative on Structural and Inflammatory Lesions in Ankylosing Spondylitis - Report of a Special Interest Group at OMERACT 10 on Sacroiliac Joint and Spine Lesions. *J Rheumatol* 2011;38:2051-4.
460. Baraliakos X, Listing J, von der Recke A, Braun J. The Natural Course of Radiographic Progression in Ankylosing Spondylitis: Differences Between Genders and Appearance of Characteristic Radiographic Features. *Curr Rheumatol Rep* 2011;13:383-7.
461. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, Krause A, Schewe S, Schneider M, Sorensen H, Schmidt R, Sieper J, Braun J. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome. *Rheumatology* 2011;50:1690-9.
462. Baraliakos X, Braun J. Spondyloarthritides. *Best Pract Res Clin Rheumatol* 2011;25:825-42.
463. Weisman M, Learch TJ, Baraliakos X, Chandran V, Gladman DD, Raychaudhuri SP, Xu HJ, Collantes-Estevez E, Vazquez-Mellado J, Mease PJ, Sieper J, Deodhar AA, Colbert RA, Clegg DO, Grp S. Current Controversies in Spondyloarthritis: SPARTAN. *J Rheumatol* 2010;37:2617-23.
464. Suppiah R, Doyle A, Rai R, Dalbeth N, Lobo M, Braun J, McQueen FM. Quantifying Bone Marrow Edema in the Rheumatoid Cervical Spine Using Magnetic Resonance Imaging. *J Rheumatol* 2010;37:1626-32.
465. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J. Different Response to Rituximab in Tumor Necrosis Factor Blocker-Naive Patients With Active Ankylosing Spondylitis and in Patients in Whom Tumor Necrosis Factor Blockers Have Failed A Twenty-Four-Week Clinical Trial. *Arthritis Rheum* 2010;62:1290-7.
466. Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. *Ann Rheum Dis* 2010;69:1338-41.
467. Pincus T, Cronstein B, Braun J. Methotrexate - the anchor drug - an introduction. *Clin Exp Rheumatol* 2010;28:S1-S2.
468. Machado P, Landewe R, Braun J, Hermann KGA, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. *Ann Rheum Dis* 2010;69:1465-70.
469. Landewe RBM, Gunther KP, Lukas C, Braun J, Combe B, Conaghan PG, Dreinhofer K, Fritschy D, Getty J, van der Heide HJL, Kvien TK, Machold K, Mihai C, Mosconi M, Nelissen R, Pascual E, Pavelka K, Pileckyte M, Puhl W, Punzi L, Ruther W, San-Julian M, Tudisco C, Westhovens R, Witso E, van der Heijde D. EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. *Ann Rheum Dis* 2010;69:12-9.
470. Kiltz U, Feldtkeller E, Braun J. German patient version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Z Rheumatol* 2010;69:171-+.
471. Kiltz U, Braun J. Use of methotrexate in patients with sarcoidosis. *Clin Exp Rheumatol* 2010;28:S183-S5.
472. Heldmann F, Braun J. Perioperative use of methotrexate. *Clin Exp Rheumatol* 2010;28:S110-S3.
473. Haeusler U, Dybowski F, Wittkaemper TA, Kisters K, Godolias G, Braun J. Arthritis of the atlanto-axial joint with inflammatory neck pain as a primary manifestation of seronegative rheumatoid arthritis. *Dtsch Med Wochenschr* 2010;135:1729-32.

474. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dorner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel P, Weinblatt ME, Weisman MH, Winthrop K. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. *Ann Rheum Dis* 2010;69:2-29.
475. Fendler C, Braun J. Use of methotrexate in inflammatory myopathies. *Clin Exp Rheumatol* 2010;28:S164-S7.
476. Dougados M, Combe B, Braun J, Landewe R, Sibia J, Cantagrel A, Feydy A, van der Heijde D, Leblanc V, Logeart I. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. *Ann Rheum Dis* 2010;69:1430-5.
477. Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, Hsu B, Gathany T, van der Heijde D. Golimumab Reduces Sleep Disturbance in Patients With Active Ankylosing Spondylitis: Results From a Randomized, Placebo-Controlled Trial. *Arthritis Care Res* 2010;62:1266-71.
478. Braun J, Sieper J. Spondyloarthritis. *Z Rheumatol* 2010;69:425-32.
479. Braun J, Rudwaleit M, Kary S, Kron M, Wong RL, Kupper H. Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. *Rheumatology* 2010;49:1578-89.
480. Braun J, Pfeilschifter J. Osteoporosis diagnosis and therapy according to the 2010 guidelines. *Z Rheumatol* 2010;69:327-38.
481. Braun J, Inman R. Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis. *Ann Rheum Dis* 2010;69:1264-8.
482. Braun J, Genth E, Vorstand D. Lest we forget. Statement by the German Rheumatology Society (DGRh) on the national socialist crimes against Jewish colleagues. *Z Rheumatol* 2010;69:770-1.
483. Braun J. Optimal administration and dosage of methotrexate. *Clin Exp Rheumatol* 2010;28:S46-S51.
484. Boonen A, Braun J, Bruinsma IEV, Huang F, Maksymowych W, Kostanjsek N, Cieza A, Stucki G, van der Heijde D. ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. *Ann Rheum Dis* 2010;69:102-7.
485. Bochkova AG, Levshakova AV, Bunchuk NV, Braun J. Spinal inflammation lesions as detected by magnetic resonance imaging in patients with early ankylosing spondylitis are more often observed in posterior structures of the spine. *Rheumatology* 2010;49:749-55.
486. Baraliakos X, Braun J. Hip involvement in ankylosing spondylitis What is the verdict? *Rheumatology* 2010;49:3-4.
487. Baraliakos X, Braun J. Anti-TNF-alpha therapy with infliximab in spondyloarthritis. *Expert Rev Clin Immunol* 2010;6:9-19.
488. Ali A, Baraliakos X, Kanawati B, Boudelal R, Teske W, Kraemer J, Theodoridis T. Microsurgical nerve root decompression in scoliotic lumbar spines-the relationship between important anatomical structures in correlation to imaging and implications for daily practice: anatomic cadaveric study Laboratory investigation. *J Neurosurg-Spine* 2010;13:123-32.
489. Zochling J, Braun J. Mortality in rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009;27:S127-S30.

490. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009;68:175-82.
491. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewe R, Assessment SpondyloArthritis Int S. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009;68:1811-8.
492. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewe R, Maksymowych W, van der Heijde D. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. *Ann Rheum Dis* 2009;68:1-44.
493. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sorensen IJ, Ozgocmen S, Roussou E, Valle-Onate R, Weber U, Wei J, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis* 2009;68:777-83.
494. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann Rheum Dis* 2009;68:770-6.
495. Rudwaleit M, Jurik AG, Hermann KGA, Landewe R, van der Heijde D, Baraliakos X, Marzo-Ortega H, Ostergaard M, Braun J, Sieper J. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. *Ann Rheum Dis* 2009;68:1520-7.
496. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J. The Early Disease Stage in Axial Spondylarthritis Results From the German Spondyloarthritis Inception Cohort. *Arthritis Rheum* 2009;60:717-27.
497. Rudwaleit M, Braun J, Sieper J. ASAS classification criteria for axial spondyloarthritis. *Z Rheumatol* 2009;68:591-3.
498. Neidhart M, Baraliakos X, Seemayer C, Zelder C, Gay RE, Michel BA, Boehm H, Gay S, Braun J. Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis. *Ann Rheum Dis* 2009;68:1334-9.
499. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D, Assessment SpondyloArthritis Int S. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009;68:18-24.
500. Kiltz U, van der Heijde D, Mielants H, Feldtkeller E, Braun J, Grp PEPI. ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version. *Ann Rheum Dis* 2009;68:1381-6.
501. Kiltz U, van der Heijde D. Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis. *Clin Exp Rheumatol* 2009;27:S108-S11.
502. Kiltz U, Rudwaleit M, Sieper J, Braun J. New aspects in the area of spondyloarthritis. *Z Rheumatol* 2009;68:420-2.

503. Kalden JR, Braun J. A glimpse into the future: recombinant proteins and small molecules for targeted therapies in rheumatic diseases. *Clin Exp Rheumatol* 2009;27:S168-S70.
504. Franck H, Braun J, Buttgereit F, Demary W, Hein G, Kekow J, Schett G, Kern PM, Kommission Osteologie D. Bone densitometry in inflammatory rheumatic diseases. Characteristics of the measurement site and disease-specific factors. *Z Rheumatol* 2009;68:845-50.
505. Fendler C, Braun J. Clinical measures in rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009;27:S80-S2.
506. Cieza A, Hilfiker R, Boonen A, van der Heijde D, Braun J, Stucki G. Towards an ICF-based clinical measure of functioning in people with ankylosing spondylitis: A methodological exploration. *Disabil Rehabil* 2009;31:528-37.
507. Braun J, van der Heijde D, Doyle MK, Han CL, Deodhar A, Inman R, de Vlam K, Burmester GR, Van den Bosch F, Xu S, Visvanathan S, Rahman MU. Improvement in Hemoglobin Levels in Patients With Ankylosing Spondylitis Treated With Infliximab. *Arthritis Rheum-Arthritis Care Res* 2009;61:1032-6.
508. Braun J, Sieper J, Pincus T. A systematic comparison between rheumatoid arthritis and ankylosing spondylitis: an introduction. *Clin Exp Rheumatol* 2009;27:S1-S2.
509. Braun J, Sieper J. Ankylosing spondylitis. Target treatment criteria. *Z Rheumatol* 2009;68:30-+.
510. Braun J, Sieper J. Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe. *Z Rheumatol* 2009;68:417-9.
511. Braun J, Sieper J. Classification criteria for rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009;27:S68-S73.
512. Braun J, Sieper J. Treatment of rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009;27:S146-S7.
513. Braun J, Rau R. An update on methotrexate. *Curr Opin Rheumatol* 2009;21:216-23.
514. Braun J, Kalden JR. Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009;27:S164-S7.
515. Braun J, Baraliakos X. Treatment of ankylosing spondylitis and other spondyloarthritides. *Curr Opin Rheumatol* 2009;21:324-34.
516. Braun J. Therapy of Spondyloarthritides. In: LopezLarrea C, DiazPena R, eds. *Molecular Mechanisms of Spondyloarthropathies*. Berlin: Springer-Verlag Berlin; 2009:133-47.
517. Baraliakos X, Listing J, von der Recke A, Braun J. The Natural Course of Radiographic Progression in Ankylosing Spondylitis - Evidence for Major Individual Variations in a Large Proportion of Patients. *J Rheumatol* 2009;36:997-1002.
518. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. Development of a Radiographic Scoring Tool for Ankylosing Spondylitis Only Based on Bone Formation: Addition of the Thoracic Spine Improves Sensitivity to Change. *Arthritis Rheum-Arthritis Care Res* 2009;61:764-71.
519. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G. Altered Skeletal Expression of Sclerostin and Its Link to Radiographic Progression in Ankylosing Spondylitis. *Arthritis Rheum* 2009;60:3257-62.

520. Zochling J, Sieper J, van der Heijde D, Braun J, Assessment Ankylosing S. Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving anti-tumor necrosis factor-alpha therapy. *J Rheumatol* 2008;35:1079-82.
521. Zochling J, Braun J. Mortality in ankylosing spondylitis. *Clin Exp Rheumatol* 2008;26:S80-S4.
522. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. *Ann Rheum Dis* 2008;67:511-7.
523. van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu WC, Baker D, Goldstein N, Braun J, Ankylosing Spondylitis Study E. Radiographic Findings Following Two Years of Infliximab Therapy in Patients With Ankylosing Spondylitis. *Arthritis Rheum* 2008;58:3063-70.
524. Song IH, Appel H, Haibel H, Loddenkemper C, Braun J, Sieper J, Rudwaleit M. New onset of Crohn's disease during treatment of active Ankylosing spondylitis with etanercept. *J Rheumatol* 2008;35:532-6.
525. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis. *Arthritis Rheum* 2008;58:649-56.
526. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. *Ann Rheum Dis* 2008;67:1276-81.
527. Kiltz U, Zochling J, Schmidt WE, Braun J. Use of NSAIDs and infection with *Helicobacter pylori* - what does the rheumatologist need to know? *Rheumatology* 2008;47:1342-7.
528. Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy-three examples. *J Rheumatol* 2008;35:2074-6.
529. Kiltz U, Feldtkeller E, Braun J. Patient evaluation of the German version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Z Rheumatol* 2008;67:694-+.
530. Inman RD, Davis JC, van der Heijde D, Dickman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu ZH, Su B, Beutler A, Braun J. Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. *Arthritis Rheum* 2008;58:3402-12.
531. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, Braun E, Sieper J. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis. *Arthritis Rheum* 2008;58:1981-91.
532. Gossec L, Dougados M, Phillips C, Hammoudeh M, de Vlam K, Pavelka K, Pham T, Braun J, Sieper J, Olivieri I, van der Heijde D, Collantes E, Stone M, Kvien TK, Asas. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. *Ann Rheum Dis* 2008;67:782-8.
533. Dybowski F, Sepp N, Bergerhausen HJ, Braun J. Successful use of anakinra to treat refractory Schnitzler's syndrome. *Clin Exp Rheumatol* 2008;26:354-7.
534. Davis JC, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. *Ann Rheum Dis* 2008;67:346-52.
535. Braun J, Sieper J. What is the most important outcome parameter in ankylosing spondylitis. *Rheumatology* 2008;47:1738-40.

536. Braun J, Kaestner P, Flaxenberg P, Waehrisch J, Hanke P, Demary W, von Hinueber U, Rockwitz K, Heitz W, Pichlmeier U, Guimbal-Schmolck C, Brandt A, Grp M-MRS. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. *Arthritis Rheum* 2008;58:73-81.
537. Braun J, Grp M-MRS. Limitations of the study of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: comment on the article by Braun et al - Reply. *Arthritis Rheum* 2008;58:2209-10.
538. Braun J, Doedhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu WC, Visvanathan S, Baker D, Goldstein N, Van Der Heijde D, Ankylosing Spondylitis Study E. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. *Arthritis Rheum-Arthritis Care Res* 2008;59:1270-8.
539. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sorensen H, Zeidler H, Sieper J. Persistent clinical efficacy and safety of anti-tumour necrosis factor a therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. *Ann Rheum Dis* 2008;67:340-5.
540. Braun J. Canadian recommendations for the management of spondyloarthritis address many different levels of patient care. *Nat Clin Pract Rheumatol* 2008;4:234-5.
541. Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. *Arthritis Res Ther* 2008;10:7.
542. Baraliakos X, Braun J. Infusion reaction to infliximab in a patient with rheumatoid arthritis after discontinuation over 1 year and readministration - Reply. *J Rheumatol* 2008;35:1897-.
543. Zochling J, Stucki G, Grill E, Braun J. A comparative study of patient-reported functional outcomes in acute rheumatoid arthritis. *J Rheumatol* 2007;34:64-9.
544. Zochling J, Grill E, Alten R, Ernst J, Stucki G, Braun J. Identification of relevant functional issues for the care of patients with acute arthritis by health professionals, using the ICF framework and a multi-disciplinary focus group approach. *Clin Exp Rheumatol* 2007;25:354-60.
545. Zochling J, Braun J. Assessments in ankylosing spondylitis. *Best Pract Res Clin Rheumatol* 2007;21:699-712.
546. Zochling J, Braun J. Quality indicators, guidelines and outcome measures in ankylosing spondylitis. *Clin Exp Rheumatol* 2007;25:S147-S52.
547. Zochling J, Baraliakos X, Hermann KG, Braun J. Magnetic resonance imaging in ankylosing spondylitis. *Curr Opin Rheumatol* 2007;19:346-52.
548. van der Heijde D, Landewe R, Hermann KG, Rudwaleit M, Ostergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RG, Lukas C, Jurik AG, Boers M, Baraliakos X, Braun J, Grp AMAW. Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? *J Rheumatol* 2007;34:871-3.
549. Rehart S, Kerschbaumer F, Braun J, Sieper J. Modern treatment of ankylosing spondylitis. *Orthopade* 2007;36:963-72.
550. Rehart S, Kerschbaumer F, Braun J, Sieper J. Modern treatment of ankylosing spondylitis. *Orthopade* 2007;36:1067-76.

551. Meyer MF, Schmidt O, Hellmich B, Schatz H, Klein HH, Braun J. Microvascular dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: relationship to soluble adhesion molecules and extraarticular manifestations. *Rheumatol Int* 2007;28:145-52.
552. Lukas C, Braun J, van der Heijde D, Hermann KGA, Rudwaleit M, Ostergaard M, Oostveen A, O'Connor P, Maksymowych WP, Lambert RGW, Jurik AG, Baraliakos X, Landewe R, Grp AMAW. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: A multireader experiment. *J Rheumatol* 2007;34:862-70.
553. Kobelt G, Sobocki P, Sieper J, Braun J. Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. *Int J Technol Assess Health Care* 2007;23:368-75.
554. Kiltz U, Brandt J, Zochling J, Braun J. Rheumatic manifestations of lymphoproliferative disorders. *Clin Exp Rheumatol* 2007;25:35-9.
555. Han CL, Smolen JS, Kavanaugh A, Van der Heijde D, Braun J, Westhovens R, Zhao N, Rahman MU, Baker D, Bala M. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. *Arthritis Res Ther* 2007;9:6.
556. Grill E, Zochling J, Stucki G, Mittrach R, Scheuringer M, Liman W, Kostanjsek N, Braun J. International classification of functioning, disability and health (ICF) core set for patients with acute arthritis. *Clin Exp Rheumatol* 2007;25:252-8.
557. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Caull A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Soriano ER, Zochling J. Consensus on a core set of domains for psoriatic arthritis. *J Rheumatol* 2007;34:1167-70.
558. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, Landewe RBM, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, van der Heijde D. International spondyloarthritis interobserver reliability exercise - The INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. *J Rheumatol* 2007;34:1740-5.
559. Braun J, Zochling J, Grill E, Liman W, Stucki G. International classification of functioning, disability and health and its significance for rheumatology. *Z Rheumatol* 2007;66:603-+.
560. Braun J, Sieper J. Ankylosing spondylitis. *Lancet* 2007;369:1379-90.
561. Braun J, Rudwaleit M, Hermann KG, Rau R. Imaging in ankylosing spondylitis. *Z Rheumatol* 2007;66:167-78.
562. Braun J, Baraliakos X, Listing J, Davis J, Van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. *Arthritis Rheum-Arthritis Care Res* 2007;57:639-47.
563. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, Braun J. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. *Ann Rheum Dis* 2007;66:910-5.
564. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sorensen H, Zeidler H, Visvanathan S, Sieper J, Braun J. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. *J Rheumatol* 2007;34:510-5.



565. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. *Rheumatology* 2007;46:1450-3.
566. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. *Ann Rheum Dis* 2006;65:423-32.
567. Zochling J, van der Heijde D, Dougados M, Braun J. The process of producing recommendations for rheumatic diseases: what is evidence? *Ann Rheum Dis* 2006;65:979-.
568. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, Dougados M, Geher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repro M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Bohm H, van Royen BJ, Braun J. ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2006;65:442-52.
569. Zochling J, Grill E, Scheuringer M, Liman W, Stucki G, Braun J. Identification of health problems in patients with acute inflammatory arthritis, using the International Classification of Functioning, Disability and Health (ICF). *Clin Exp Rheumatol* 2006;24:239-46.
570. Zochling J, Braun J, van der Heijde D. Assessments in ankylosing spondylitis. *Best Pract Res Clin Rheumatol* 2006;20:521-37.
571. Zochling J, Braun J. Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis. *Expert Opin Pharmacother* 2006;7:869-83.
572. Zochling J, Braun J. Remission in ankylosing spondylitis. *Clin Exp Rheumatol* 2006;24:S88-S92.
573. Zochling J, Bonjean M, Grill E, Scheuringer M, Stucki G, Braun J. Systematic review of measures and their concepts used in published studies focusing on the treatment of acute inflammatory arthritis. *Clin Rheumatol* 2006;25:807-13.
574. Zochling J, Bohl-Buhler MHJ, Baraliakos X, Feldtkeller E, Braun J. Infection and work stress are potential triggers of ankylosing spondylitis. *Clin Rheumatol* 2006;25:660-6.
575. Zochling J, Bohl-Buhler MHJ, Baraliakos X, Feldtkeller E, Braun J. The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. *Clin Rheumatol* 2006;25:648-58.
576. Zochling J, Bohl-Buhler MHJ, Baraliakos X, Feldtkeller E, Braun J. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis - a population-based survey. *Clin Rheumatol* 2006;25:794-800.
577. van Echteld I, Cieza A, Boonen A, Stucki G, Zochling J, Braun J, van der Heijde D. Identification of the most common problems by patients with ankylosing spondylitis using the International Classification of Functioning, Disability and Health. *J Rheumatol* 2006;33:2475-83.
578. Van der Heijde D, Han CL, DeVlam K, Burmester G, Van den Bosch F, Williamson P, Bala M, Han J, Braun J. Infliximab improves productivity and reduces workday loss in patients with Ankylosing Spondylitis: Results from a randomized, placebo-controlled trial. *Arthritis Rheum-Arthritis Care Res* 2006;55:569-74.
579. Stier-Jarmer M, Liman W, Stucki G, Braun J. Structures of acute rheumatic care. *Z Rheumatol* 2006;65:747-60.
580. Sieper J, Rudwaleit M, Khan MA, Braun J. Concepts and epidemiology of spondyloarthritis. *Best Pract Res Clin Rheumatol* 2006;20:401-17.

581. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis - A reassessment of the clinical history for application as classification and diagnostic criteria. *Arthritis Rheum* 2006;54:569-78.
582. Rau R, Wasserberg S, Backhaus M, Braun J, Edelmann E, Kellner H, Ostendorf B, Rudwaleit M, Sandrock D, Schalm J, Scherer A, Schmidt W. Imaging methods in rheumatology: imaging in psoriasis arthritis (PsA). *Z Rheumatol* 2006;65:159-67.
583. Pham T, Landewe R, van der Linden S, Dougados M, Sieper J, Braun J, Davis J, Rudwaleit M, Collantes E, Burgos-Vargas R, Edmonds J, Olivieri I, van der Horst-Bruinsma I, Mielants H, Stone M, Emery P, van der Heijde D. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. *Ann Rheum Dis* 2006;65:1620-5.
584. Natsis K, Baraliakos X, Appell HJ, Tsikaras P, Gigis I, Koebe J. The course of the greater occipital nerve in the suboccipital region: A proposal for setting landmarks for local anesthesia in patients with occipital neuralgia. *Clin Anat* 2006;19:332-6.
585. Heldmann F, Brandt J, Schoppe H, Braun J. A 46-year-old-patient with granulomatous prostatitis, arthralgia and haemorrhagic rhinitis. *Dtsch Med Wochenschr* 2006;131:22-5.
586. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, Braun J, Sieper J. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week openlabel trial. *Arthritis Rheum* 2006;54:678-81.
587. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. *Ann Rheum Dis* 2006;65:713-20.
588. Dybowski F, Jakobs B, Altmeyer P, Braun J. Successful treatment of clinical manifestations of Muckle-Wells syndrome with anakinra. *Dtsch Med Wochenschr* 2006;131:1863-6.
589. Davis JC, Dougados M, Braun J, Sieper J, van der Heijde D, van der Linden S. Definition of disease duration in ankylosing spondylitis: reassessing the concept. *Ann Rheum Dis* 2006;65:1518-20.
590. Braun J, Zochling J, Marker-Hermann E, Stucki G, Bohm H, Rudwaleit M, Zeidler H, Sieper J. Recommendations for the management of ankylosing spondylitis after ASAS/EULAR. Evaluation in the German language area. *Z Rheumatol* 2006;65:728-+.
591. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, Gomor B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. *Ann Rheum Dis* 2006;65:1147-53.
592. Braun J, Wassenberg S. Outcome parameters for use in psoriatic arthritis. *Z Rheumatol* 2006;65:110-+.
593. Braun J, van der Heijde D. Spondyloarthropathies. *Best Pract Res Clin Rheumatol* 2006;20:399-400.
594. Braun J, Sieper J. Early diagnosis of spondyloarthritis. *Nat Clin Pract Rheumatol* 2006;2:536-45.
595. Braun J, Sieper J. Spondylarthritides. *Z Rheumatol* 2006;65:613-31.
596. Braun J, Landewe R, Hermann KGA, Han J, Yan S, Williamson P, van der Heijde D, Grp AS. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab - Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. *Arthritis Rheum* 2006;54:1646-52.

597. Braun J, Dybowski F, Fendler C, Bergerhausen HJ, Sieper J. Financial basis for the prescription of TNF-blockers in Germany. *Aktuelle Rheumatol* 2006;31:322-8.
598. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, Grp AW. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. *Ann Rheum Dis* 2006;65:316-20.
599. Braun J. Conventional radiography versus MRI: how best to diagnose spondyloarthritis? *Nat Clin Pract Rheumatol* 2006;2:526-7.
600. Brandt J, Braun J. Anti-TNF-alpha agents in the treatment of psoriatic arthritis. *Expert Opin Biol Ther* 2006;6:99-107.
601. Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewe R, Braun J, Brandt J, Sieper J, van der Linden S. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. *Ann Rheum Dis* 2006;65:201-8.
602. Baraliakos X, Braun J. Magnetic resonance imaging in spondyloarthropathies. *Joint Bone Spine* 2006;73:1-3.
603. Althoff CE, Hermann KG, Braun J, Sieper J. Ankylosing spondylitis - current state of imaging including scoring methods. *Z Rheumatol* 2006;65:688-+.
604. Alberding A, Stierle H, Brandt J, Braun J. Effectiveness and safety of radium chloride in the treatment of ankylosing spondylitis. Results of an observational study. *Z Rheumatol* 2006;65:245-51.
605. Zochling J, Braun J. Management and treatment of ankylosing spondylitis. *Curr Opin Rheumatol* 2005;17:418-25.
606. Zochling J, Braun J. Assessment of ankylosing spondylitis. *Clin Exp Rheumatol* 2005;23:S133-S41.
607. Zochling J, Brandt J, Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. *Rheumatology* 2005;44:1483-91.
608. van der Heijde D, Landewe RBM, Hermann KGA, Jurik AG, Maksymowych WP, Rudwaleit M, O'Connor PJ, Braun J, Asas Omeract Mri AS. Application of the OMERACT filter to scoring methods for magnetic resonance imaging of the sacroiliac joints and the spine. Recommendations for a research agenda at OMERACT 7. *J Rheumatol* 2005;32:2042-7.
609. van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, Hallegua DS, Bruckel J. Assessment in ankylosing spondylitis International Working Group/spondylitis association of America recommendations for conducting clinical trials in ankylosing spondylitis. *Arthritis Rheum* 2005;52:386-94.
610. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun K, Breban M, Burmester G, Clark M, Deadhar A, Douga-dos M, Edwards W, Gaston J, Inman R, Kellner H, Leirisalo-Repo M, Maksymowych W, Moreland L, Peloso P, Reveille J, Ritchlin C, Schneider M, Smith D, Steinfeld S, Veys E, de Vlam K, Zeidler H, Ankylosing Spondylitis S. Efficacy and safety of infliximab in patients with ankylosing spondylitis - Results of a randomized, placebo-controlled trial (ASSERT). *Arthritis Rheum* 2005;52:582-91.
611. van der Heijde D, Braun J, Landewe R, Davis J, Sieper J, van der Linden S, Dougados M. ASessment in Ankylosin Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis? *Ann Rheum Dis* 2005;64:108-9.
612. Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. *Rheumatology* 2005;44:1525-30.

613. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. *Ann Rheum Dis* 2005;64:1305-10.
614. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept (vol 64, pg 1305, 2005). *Ann Rheum Dis* 2005;64:1668-.
615. Nash P, Mease PJ, Braun J, van der Heijde D. Seronegative spondyloarthropathies: to lump or split? *Ann Rheum Dis* 2005;64:9-13.
616. Meyer MF, Czaplowski H, Braun J, Hellmich B, Schatz H, Klein HH. Lack of a difference in increased capillary blood cell velocity in the skin over proximal interphalangeal joints between rheumatoid arthritis and osteoarthritis. *Microvasc Res* 2005;70:1-6.
617. Leistner K, Stier-Jarmer M, Berleth B, Braun J, Koenig E, Liman W, Luttje D, Meindl R, Pientka L, Weber G, Stucki G. Early rehabilitation care in the acute hospital setting - Definition and indication results of the expert group „Early rehabilitation care in the acute hospital setting". *Physik Med Rehabilitationsmed Kurort* 2005;15:157-67.
618. Landewe RBM, Hermann KGA, van der Heijde D, Baraliakos X, Jurik AG, Lambert RG, Ostergaard M, Rudwaleit M, Salonen DC, Braun J, Grp AOMAW. Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. *J Rheumatol* 2005;32:2050-5.
619. Kohler S, Thiel A, Rudwaleit M, Sieper J, Braun J. CD27(+) memory and CD27(-) effector CD8(+) T cells are responsible for a decreased production of proinflammatory cytokines in HLA B27-positive subjects. *Clin Exp Rheumatol* 2005;23:840-6.
620. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. *J Rheumatol* 2005;32:1290-+.
621. Hermann KGA, Landewe RBM, Braun J, van der Heijde D. Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: Is paramagnetic contrast medium necessary? *J Rheumatol* 2005;32:2056-60.
622. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. *Ann Rheum Dis* 2005;64:124-6.
623. Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. *Ann Rheum Dis* 2005;64:1557-62.
624. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Sieper J. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. *Ann Rheum Dis* 2005;64:229-34.
625. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. *Arthritis Rheum* 2005;52:2447-51.
626. Braun J, Baraliakos X, Godolias G, Bohm H. Therapy of ankylosing spondylitis - a review. Part I: Conventional medical treatment and surgical therapy. *Scand J Rheumatol* 2005;34:97-108.
627. Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthritides. *Scand J Rheumatol* 2005;34:178-90.

628. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Sieper J. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. *Rheumatology* 2005;44:670-6.
629. Braun J. Infliximab in ankylosing spondylitis. *Drugs* 2005;65:1293-4.
630. Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. *Rheumatology* 2005;44:342-8.
631. Bollow M, Hermann KGA, Biedermann T, Sieper J, Schontube M, Braun J. Very early spondyloarthritis: where the inflammation in the sacroiliac joints starts. *Ann Rheum Dis* 2005;64:1644-6.
632. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor a antibody infliximab. *Ann Rheum Dis* 2005;64:1462-6.
633. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J. Clinical response to withdrawal of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab (vol 7, pg R439, 2005). *Arthritis Res Ther* 2005;7:113-.
634. Baraliakos X, Listing J, Brandt J, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. *Arthritis Res Ther* 2005;7:R439-R44.
635. Baraliakos X, Landewe R, Hermann KG, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. *Ann Rheum Dis* 2005;64:730-4.
636. Baraliakos X, Hermann KGA, Landewe R, Listing J, Golder W, Brandt J, Rudwaleit M, Bollow M, Sieper J, van der Heijde D, Braun J. Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T-1 and short tau inversion recovery (STIR) sequences. *Ann Rheum Dis* 2005;64:1141-4.
637. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with Ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. *Arthritis Rheum* 2005;52:1216-23.
638. Baraliakos X, Brandt J, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data. *Arthritis Rheum-Arthritis Care Res* 2005;53:856-63.
639. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. *Ann Rheum Dis* 2004;63:535-43.
640. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. *Ann Rheum Dis* 2004;63:665-70.
641. Peloso PM, Braun J. Expanding the armamentarium for the spondyloarthropathies. *Arthritis Res Ther* 2004;6:S36-S43.

642. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact of anti-tumour necrosis factor a treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. *Ann Rheum Dis* 2004;63:1670-2.
643. Hermann KGA, Braun J, Fischer T, Reissbauer H, Bollow M. Magnetic resonance imaging of sacroiliitis: anatomy, histological pathology, MR-morphology, and grading. *Radiologe* 2004;44:217-28.
644. Haibel H, Niewerth M, Brandt J, Rudwaleit M, Listing J, Sieper J, Braun J. Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab - A comparison of SF-36 and SF-12. *Z Rheumatol* 2004;63:393-401.
645. Franck H, Braun J, Buttgereit F, Dreher R, Hein G, Kekow J. Specialities in therapy of osteoporosis in inflammatory joint disease. *Z Rheumatol* 2004;63:223-9.
646. Braun J, Sieper J. Biological therapies in the spondyloarthritides - the current state. *Rheumatology* 2004;43:1072-84.
647. Braun J, Baraliakos X, Golder W, Hermann KG, Listing J, Brandt J, Rudwaleit M, Zuehlsdorf S, Bollow M, Sieper J, van der Heijde D. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. *Ann Rheum Dis* 2004;63:1046-55.
648. Braun J. Epidemiology and prognosis of ankylosing spondylitis. *Radiologe* 2004;44:209-+.
649. Brandt J, Sieper J, Braun J. Current therapy with TNF alpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis. *Z Rheumatol* 2004;63:203-10.
650. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. *Ann Rheum Dis* 2004;63:1438-44.
651. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. *J Rheumatol* 2004;31:531-8.
652. Baraliakos X, Braun J. Current concepts in the therapy of the spondyloarthritides. *Biodrugs* 2004;18:307-14.
653. Zou JX, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. *Arthritis Rheum* 2003;48:780-90.
654. Zou J, Zhang Y, Thiel A, Rudwaleit M, Shi SL, Radbruch A, Poole R, Braun J, Sieper J. Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. *Rheumatology* 2003;42:846-55.
655. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. *Ann Rheum Dis* 2003;62:561-4.
656. van Tubergen A, van der Heijde D, Anderson J, Landewe R, Dougados M, Braun J, Bellamy N, Udre G, van der Linden S, Grp AW. Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. *Ann Rheum Dis* 2003;62:215-21.

657. Muche B, Bollow M, Francois RJ, Sieper J, Hamm B, Braun J. Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis - A detailed analysis by contrast-enhanced magnetic resonance imaging. *Arthritis Rheum* 2003;48:1374-84.
658. Lautermann D, Specker C, Braun J. Angiological diagnostics in rheumatology. *Aktuelle Rheumatol* 2003;28:73-+.
659. Haibel H, Brandt J, Rudwaleit M, Soerensen H, Sieper J, Braun J. Treatment of active ankylosing spondylitis with pamidronate. *Rheumatology* 2003;42:3.
660. Fischer T, Biedermann T, Hermann KGA, Diekmann F, Braun J, Hamm B, Bollow M. Sacroiliitis in children with spondyloarthropathy: Therapeutic effect of CT-guided intra-articular corticosteroid injection. *Rofo-Fortschr Gebiet Rontgenstrahlen Bildgeb Verfahr* 2003;175:814-21.
661. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. *Rheumatol Int* 2003;23:61-6.
662. Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. *Expert Opin Investig Drugs* 2003;12:1097-109.
663. Braun J, Sieper J, van der Heijde D. Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal. *Ann Rheum Dis* 2003;62:1023-4.
664. Braun J, Sieper J. Role of novel biological therapies in psoriatic arthritis - Effects on joints and skin. *Biodrugs* 2003;17:187-99.
665. Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. *Expert Opin Biol Ther* 2003;3:141-68.
666. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D, Grp AW. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. *Ann Rheum Dis* 2003;62:817-24.
667. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Reddig J, Sieper J. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis - An open, observational, extension study of a three-month, randomized, placebo-controlled trial. *Arthritis Rheum* 2003;48:2224-33.
668. Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J. Biologic therapies in the spondyloarthritis: new opportunities, new challenges. *Curr Opin Rheumatol* 2003;15:394-407.
669. Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, Bolow M, Sieper J, van der Heijde D. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab - Evaluation of a new scoring system. *Arthritis Rheum* 2003;48:1126-36.
670. Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, Sieper J. Aclaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. *Z Rheumatol* 2003;62:264-73.
671. Brandt J, Sieper J, Braun J. Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists. *Z Rheumatol* 2003;62:218-+.
672. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. *Arthritis Rheum* 2003;48:1667-75.

673. Zou JX, Braun J, Sieper J. Immunological basis for the use of TNF alpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. *Clin Exp Rheumatol* 2002;20:S34-S7.
674. Zou J, Rudwaleit M, Thiel A, Lauster R, Braun J, Sieper J. T cell response to human HSP60 and yersinia 19 kDa in ankylosing spondylitis and rheumatoid arthritis: no evidence for a causal role of these antigens in the pathogenesis. *Ann Rheum Dis* 2002;61:473-4.
675. van der Heijde D, Braun J, McGonagle D, Siegel J. Treatment trials in ankylosing spondylitis: current and future considerations. *Ann Rheum Dis* 2002;61:24-32.
676. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. *Ann Rheum Dis* 2002;61:8-18.
677. Sieper J, Braun J. Diagnosis and antibiotic treatment of reactive arthritis. *Dtsch Med Wochenschr* 2002;127:1893-6.
678. Schmidt WA, Hauer RW, Banzer D, Bohl-Buhler M, Braun J, Mellerowicz H, Sattler H, Backhaus M. Technique and diagnostic value of musculoskeletal ultrasonography in rheumatology - Part 2: Ultrasonography of the hip. *Z Rheumatol* 2002;61:180-8.
679. Schmidt WA, Hauer RW, Banzer D, Bohl-Buhler M, Braun J, Mellerowicz H, Sattler H, Backhaus M. Technique and diagnostic value of musculoskeletal ultrasonography in rheumatology - Part 3: sonography of ankle, foot, and toes. *Z Rheumatol* 2002;61:279-90.
680. Mellerowicz H, Hauer RW, Schmidt WA, Bohl-Buhler M, Banzer D, Sattler H, Braun J, Backhaus M. Technique and diagnostic value of musculoskeletal ultrasonography in rheumatology. Part 5: Ultrasonography of the shoulder. *Z Rheumatol* 2002;61:577-89.
681. Maksymowych WP, Breban M, Braun J. Ankylosing spondylitis and current disease-controlling agents: do they work? *Best Pract Res Clin Rheumatol* 2002;16:619-30.
682. Lautermann D, Braun J. Ankylosing spondylitis - Cardiac manifestations. *Clin Exp Rheumatol* 2002;20:S11-S5.
683. Lakomek HJ, Hulsemann JL, Koeneke N, Lehmann H, Bergerhausen HJ, Fiori W, Loskamp N, Roeder N. Coding recommendations for rheumatology - a guide for clinical practice. *Z Rheumatol* 2002;61:311-35.
684. Kiltz U, Pfaffenbach B, Schmidt WE, Adamek RJ. The lack of influence of CagA positive *Helicobacter pylori* strains on gastro-oesophageal reflux disease. *Eur J Gastroenterol Hepatol* 2002;14:979-84.
685. Haibel H, Braun J, Maksymowych WP. Bisphosphonates - Targeting bone in the treatment of spondyloarthritis. *Clin Exp Rheumatol* 2002;20:S162-S6.
686. Feldtkeller E, Braun J. Prevalence of spondyloarthropathy in Japan. *J Rheumatol* 2002;29:1105-7.
687. Braun J, van der Heijde D, Pincus T. Novel anti-rheumatic therapies challenge old views on ankylosing spondylitis and other spondyloarthritides. *Clin Exp Rheumatol* 2002;20:S1-S2.
688. Braun J, van der Heijde D, Dougados M, Emery P, Khan MA, Sieper J, van der Linden S. Staging of patients with ankylosing spondylitis: a preliminary proposal. *Ann Rheum Dis* 2002;61:19-23.
689. Braun J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. *Best Pract Res Clin Rheumatol* 2002;16:573-604.
690. Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H. Anti-tumour necrosis factor a therapy for ankylosing spondylitis: international experience. *Ann Rheum Dis* 2002;61:51-60.



691. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. *Arthritis Res* 2002;4:307-21.
692. Braun J, Sieper J. Refractory inflammatory heel pain in spondylarthropathy: a significant response to infliximab documented by ultrasound - Reply. *Arthritis Rheum* 2002;46:841-2.
693. Braun J, Sieper J. New and old therapeutic options for ankylosing spondylitis - Is there an indication for sulfasalazine? *Z Rheumatol* 2002;61:151-+.
694. Braun J, Sieper J. Case series of selective anti-tumor necrosis factor a therapy using infliximab in patients with nonresponsive chronic HLA-B27-associated anterior uveitis: comment on the articles by Brandt et al - Reply. *Arthritis Rheum* 2002;46:2822-4.
695. Braun J, Sieper J. Anti-TNF therapy and the spondyloarthritides: Who should be treated? *Clin Exp Rheumatol* 2002;20:S187-S.
696. Braun J, Sieper J. Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002. *Ann Rheum Dis* 2002;61:61-7.
697. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. *Clin Exp Rheumatol* 2002;20:S16-S22.
698. Braun J, Golder W, Bollow M, Sieper J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. *Clin Exp Rheumatol* 2002;20:S178-S84.
699. Braun J, Breban M, Maksymowycz WP. Therapy for ankylosing spondylitis: new treatment modalities. *Best Pract Res Clin Rheumatol* 2002;16:631-51.
700. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet* 2002;359:1187-93.
701. Brandt J, Sieper J, Braun J. Infliximab in the treatment of active and severe ankylosing spondylitis. *Clin Exp Rheumatol* 2002;20:S106-S10.
702. Brandt J, Maier T, Rudwaleit M, Kuhl U, Hiepe F, Sieper J, Braun J. Co-occurrence of spondyloarthropathy and connective tissue disease: Development of Sjogren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis. *Clin Exp Rheumatol* 2002;20:80-4.
703. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. *J Rheumatol* 2002;29:118-22.
704. Bollow M, Enzweiler C, Taupitz M, Golder W, Hamm B, Sieper J, Braun J. Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides. *Clin Exp Rheumatol* 2002;20:S167-S74.
705. Backhaus M, Schmidt WA, Mellerowicz H, Bohl-Buhler M, Banzer D, Braun J, Sattler H, Hauer RW. Technique and diagnostic value of musculoskeletal ultrasonography in rheumatology. Part 4: Ultrasonography of the elbow. *Z Rheumatol* 2002;61:415-25.
706. Backhaus M, Schmidt WA, Mellerowicz H, Bohl-Buhler M, Banzer D, Braun J, Sattler H, Hauer RW. Technique and diagnostic value of musculoskeletal ultrasonography in rheumatology. Part 6: Ultrasonography of the wrist/hand. *Z Rheumatol* 2002;61:674-87.

707. Antoni C, Braun J. Side effects of anti-TNF therapy: Current knowledge. *Clin Exp Rheumatol* 2002;20:S152-S7.
708. Sieper J, Braun J. New treatment options in ankylosing spondylitis: a role for anti-TNF alpha therapy. *Ann Rheum Dis* 2001;60:III58-III61.
709. Sieper J, Braun J. Treatment options in spondyloarthropathies. *Z Rheumatol* 2001;60:458-63.
710. Semler J, Braun J. The clinical picture of osteoporosis in inflammatory rheumatic diseases. *Aktuelle Rheumatol* 2001;26:101-5.
711. Hauer RW, Schmidt WA, Bohl-Buhler M, Banzer D, Mellerowicz H, Sattler H, Braun T, Backhaus M. Technique and diagnostic value of musculoskeletal ultrasonography in rheumatology Part 1: Ultrasonography of the knee. *Z Rheumatol* 2001;60:139-47.
712. Francois RJ, Braun J, Khan MA. Entheses and enthesitis: a histopathologic review and relevance to spondyloarthritides. *Curr Opin Rheumatol* 2001;13:255-64.
713. Braun J, Sieper J. Osteoporosis due to steroid therapy. *Orthopade* 2001;30:444-50.
714. Braun J, Lemmel EM, Manger B, Rau R, Sorensen H, Sieper J. Therapy of ankylosing spondylitis (AS) with radium chloride ((224)SpondyAT (R)). *Z Rheumatol* 2001;60:74-83.
715. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. *Curr Opin Rheumatol* 2001;13:245-9.
716. Braun J, Brandt J, Sieper I. Therapy with monoclonal antibodies against TNF alpha in ankylosing spondylitis and other rheumatic diseases. *Dtsch Z Sportmed* 2001;52:50-6.
717. Brandt J, Haibel H, Sieper J, Reddig J, Braun J. Infliximab treatment of severe ankylosing spondylitis: One-year followup. *Arthritis Rheum* 2001;44:2936-7.
718. Wittenborg A, Bock PR, Hanisch J, Saller R, Schneider B. Comparative epidemiological study in patients with rheumatic diseases illustrated in an example of a treatment with non-steroidal anti-inflammatory drugs versus an oral enzyme combination. *Arzneimittelforschung* 2000;50:728-38.
719. Poehlau D, Kiltz U, Rieks M, Hoffmann V, Rebmann V, Schimrigk S, Grosse-Wilde H, Przuntek H. Therapeutic immunoadsorption increases the level of circulating soluble HLA molecules. *Vox Sang* 2000;78:119-21.

2021

1-27

2020

28-100

2019

101-153

2018

154-199

2017

200-242

2016

243-290

2015

291-318

2014

319-361

2013

362-386

2012

387-427

2011

428-462

2010

463-488

2009

489-519

2008

520-542

2007

543-565

2006

566-605

2005

606-638

2004

639-652

2003

653-672

2002

673-707

2001

708-717

2000

718,719